



**DELAWARE HEALTH
AND SOCIAL SERVICES**

DIVISION OF MEDICAID &
MEDICAL ASSISTANCE

Delaware Medical Assistance Program

2026 Delaware Medicaid Preferred Drug List (PDL)

- Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.
- Be advised that any prior authorization criterion provided here is for **FEE-FOR-SERVICE (FFS) MEMBERS ONLY**. Prior authorization forms for FFS members can be found on the Pharmacy Corner at: <https://medicaid.dhss.delaware.gov/provider/Home/PharmacyCornerLanding/tabid/2096/Default.aspx>
- Prior authorizations for members enrolled with a Managed Care Organization (MCO) should be processed through the MCO following MCO criteria.
 - Highmark Health Options (HHO) criteria can be reviewed at <https://client.formularynavigator.com/Search.aspx?siteCode=9768635417>
 - AmeriHealth Caritas criteria can be reviewed at <http://www.amerihealthcaritasde.com/provider/resources/pharmacy-prior-auth.aspx>
 - Delaware First Health criteria can be reviewed at <https://www.delawarefirstthealth.com/providers/resources/clinical-payment-policies.html>
- For brand-name medications not on the Brand over Generic (BoG) list to be considered, providers must submit a prior authorization form with documentation of medical trial of the generic and outcome electronically via the DMAP Provider Portal.
 - A brand-name agent highlighted in **yellow** on the PDL is preferred over its generic. Please note that some brand name agents may not be listed on the PDL.
 - Please refer to the Delaware Pharmacy Corner website for a complete listing of BoG agents at <https://medicaid.dhss.delaware.gov/provider/Home/PharmacyCornerLanding/tabid/2096/Default.aspx>

The DMAP may limit the duration of time that a member may receive medication during a 12-month period or may establish a lifetime limit for particular classes of drugs or specific products.

ACNE AGENTS.....	1
ORAL	1
TOPICAL	1
ANALGESICS	2
ANALGESICS, NARCOTIC LONG-ACTING	2
ANALGESICS, NARCOTIC SHORT-ACTING, NON-INJECTABLE	2
ANALGESICS, NON-NARCOTIC SHORT-ACTING	3
ANTIHYPERTENSIVES, ORAL	3
ANTIMIGRAINE AGENTS, PROPHYLAXIS	3
ANTIMIGRAINE AGENTS, TREATMENT	3
CYTOKINE AND CAM ANTAGONISTS, ORAL/SUBCUTANEOUS	4
NSAIDs, NASAL/ORAL/TOPICAL	5
OPIATE DEPENDENCE TREATMENTS	6
ANTIDOTES.....	6
CHELATING AGENTS	6

OPIATE OVERDOSE TREATMENTS	6
ANTI-INFECTIVE AGENTS	6
ANTIBIOTICS, GI	6
ANTIBIOTICS, INHALED	7
ANTIBIOTICS, VAGINAL	7
ANTIFUNGALS, ORAL	7
ANTIVIRALS, ANTIRETROVIRALS	7
ANTIVIRALS, COVID - 19	8
ANTIVIRALS, HEPATITIS C AGENTS	8
ANTIVIRALS, ORAL/INHALATION	9
CEPHALOSPORINS, ORAL	9
FLUOROQUINOLONES, ORAL	9
LINCOSAMIDES/OXAZOLIDINONES/STREPTOGRAMINS	9
MACROLIDES	10
PENICILLINS, ORAL/IM	10
TETRACYCLINES	10
URINARY ANTI-INFECTIVES	10
ANTINEOPLASTICS	11
ONCOLOGY AGENTS	11
CARDIOVASCULAR AGENTS	11
ANGIOTENSIN MODULATORS	11
ANGIOTENSIN MODULATOR/CALCIUM CHANNEL BLOCKER COMBINATIONS	12
ANTIHYPERTENSIVES, SYMPATHOLYTIC	12
BETA BLOCKERS	13
CALCIUM CHANNEL BLOCKERS	13
DIURETICS	14
EPINEPHRINE, SELF-INJECTED	14
HEART FAILURE DRUGS	14
LIPOTROPICS, OTHER	14
LIPOTROPICS, STATINS	15
PAH AGENTS, ORAL & INHALED	15
VASODILATORS, CORONARY	16
CENTRAL NERVOUS SYSTEM DRUGS	16

ANTIDEPRESSANTS, OTHER	16
ANTIDEPRESSANTS, SSRIs	17
ANTIPSYCHOTICS, ORAL/INHALATION	17
ANTIPSYCHOTICS, INJECTABLE/INHALATION	18
ANXIOLYTICS	18
MOOD STABILIZERS	18
SEDATIVE HYPNOTICS	19
DIABETIC SUPPLY LIST	19
ENDOCRINE AND METABOLIC DRUGS	19
ANDROGENIC AGENTS.....	19
BONE RESORPTION SUPPRESSION AND RELATED AGENTS.....	20
CONTRACEPTIVES, ORAL – BIPHASIC	20
CONTRACEPTIVES, ORAL - COMBINATION.....	21
CONTRACEPTIVES, ORAL - EXTENDED CYCLE.....	21
CONTRACEPTIVES, ORAL - PROGESTINS.....	21
CONTRACEPTIVES, ORAL – TRIPHASIC	22
CONTRACEPTIVES – IUDs / IMPLANTS	22
CONTRACEPTIVES – PATCHES.....	22
CONTRACEPTIVES – VAGINAL RINGS	22
GROWTH HORMONES.....	23
HYPERPARATHYROIDS	23
HYPOGLYCEMIA TREATMENTS	23
HYPOGLYCEMICS, ALPHA-GLUCOSIDASE INHIBITORS	23
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS: DPP-4 INHIBITORS	23
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS: GLP-1 RAs.....	24
HYPOGLYCEMICS, INSULINS.....	24
HYPOGLYCEMICS, MEGLITINIDES	25
HYPOGLYCEMICS, METFORMINS	25
HYPOGLYCEMICS, SGLT2 INHIBITORS	25
HYPOGLYCEMICS, TZDs.....	25
GLUCOCORTICOIDS, ORAL	25
NON-ALCOHOLIC STEATOHEPATITIS (NASH) TREATMENT AGENTS.....	26
PELVIC DISORDERS – ENDOMETRIOSIS, UTERINE FIBROIDS	26

PITUITARY SUPPRESSANTS, CENTRAL PRECOCIOUS PUBERTY (CPP)	26
POTASSIUM REMOVING AGENTS	26
PROGESTATIONAL AGENTS	27
THYROID HORMONES	27
UREA CYCLE DISORDER AGENTS	27
VASOMOTOR SYMPTOMS	27
GASTROINTESTINAL AGENTS	27
ANTIEMETICS, ORAL/TRANSDERMAL	27
BILE SALTS	28
BOWEL PREP	28
CONSTIPATION – IBS, ORAL	28
DIARRHEA – IBS, ORAL	28
H. PYLORI TREATMENTS	28
HISTAMINE II RECEPTOR BLOCKERS	29
HYPERPHOSPHATEMIA AGENTS, OTHER	29
HYPERPHOSPHATEMIA AGENTS, PHOSPHATE BINDERS	29
PANCREATIC ENZYMES	29
PROTON PUMP INHIBITORS	29
ULCERATIVE COLITIS AGENTS	30
GENE THERAPY	30
CENTRAL NERVOUS SYSTEM, SPINAL MUSCULAR ATROPHY	30
HEMATOLOGICAL, SICKLE CELL DISEASE	30
TOPICAL, RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA	30
GENITOURINARY PRODUCTS	30
BLADDER RELAXANT PREPARATIONS	30
BPH TREATMENTS	31
HEMATOLOGICAL AGENTS	31
ANTICOAGULANTS, ORAL/SQ	31
HEMOPHILIA A/VWD	31
HEMOPHILIA B	32
COLONY STIMULATING FACTORS	32
ERYTHROPOIESIS STIMULATING PROTEINS	32
HAE TREATMENTS	33

PLATELET AGGREGATION INHIBITORS	33
SICKLE CELL ANEMIA AGENTS	33
THROMBOPOIETICS	33
IMMUNE GLOBULINS	34
IMMUNE GLOBULINS	34
MEDICAL DEVICES AND SUPPLIES	34
BLOOD GLUCOSE METERS, TEST STRIPS	34
CONTINUOUS GLUCOSE MONITORS (CGMs)	34
INSULIN PUMPS	34
RESPIRATORY DEVICES	34
NEUROMUSCULAR DRUGS	35
ANTICONSULTANTS, ORAL/RECTAL/NASAL	35
ANTIPARKINSON'S AGENTS, ORAL/TRANSDERMAL	36
SKELETAL MUSCLE RELAXANTS	36
NUTRITIONAL PRODUCTS	37
PRENATAL VITAMINS	37
OBESITY TREATMENT AGENTS	37
OVER THE COUNTER DRUGS	38
PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS	38
ALZHEIMER'S AGENTS	38
MOVEMENT DISORDER	38
MULTIPLE SCLEROSIS	38
NEUROPATHIC PAIN	39
RESPIRATORY AGENTS	39
ANTIHISTAMINES, MINIMALLY SEDATING	39
BRONCHODILATORS, BETA AGONIST	40
COPD AGENTS, SINGLE & DUAL AGENT COMBINATIONS	40
COUGH AND COLD	40
GLUCOCORTICIDS, INHALED	41
INTRANASAL RHINITIS AGENTS	41
LEUKOTRIENE RECEPTOR ANTAGONISTS	42
MABs-ANTI-IL, ANTI-IGE	42
STIMULANTS AND RELATED AGENTS	42
NARCOLEPTIC AGENTS	42

STIMULANTS AND RELATED AGENTS – LONG-ACTING, AMPHETAMINE-LIKE AGENTS	42
STIMULANTS AND RELATED AGENTS – LONG-ACTING	43
STIMULANTS AND RELATED AGENTS – LONG-ACTING, OTHER	43
STIMULANTS AND RELATED AGENTS – SHORT-ACTING	43
STIMULANTS AND RELATED AGENTS – SHORT-ACTING, METHYLPHENIDATE-LIKE AGENTS	43
SMOKING CESSATION	44
SMOKING CESSATION PRODUCTS	44
TOPICAL PRODUCTS	44
ANTIBIOTICS, TOPICAL	44
ANTIFUNGALS, TOPICAL	44
ANTIPARASITICS, TOPICAL	45
ANTIPSORIATIC AGENTS, ORAL	45
ANTIPSORIATIC AGENTS, TOPICAL	45
ANTIVIRALS, TOPICAL	45
IMMUNOMODULATORS, ATOPIC DERMATITIS	45
IMMUNOMODULATORS, TOPICAL	46
OPHTHALMICS, ALLERGIC CONJUNCTIVITIS	46
OPHTHALMICS, ANTIBIOTICS	46
OPHTHALMICS, ANTIBIOTIC-STEROID COMBINATION	46
OPHTHALMICS, ANTI-INFLAMMATORIES	47
OPHTHALMICS, GLAUCOMA AGENTS	47
OPHTHALMICS, IMMUNOMODULATORS	48
OTIC ANTIBIOTICS	48
OTIC ANTI-INFECTIVES, ANESTHETICS	48
ROSACEA AGENTS, TOPICAL	48
STEROIDS, TOPICAL	49

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
ACNE AGENTS		
ORAL		Review Schedule: 2nd Quarter
AMNESTEEM (isotretinoin) CLARAVIS (isotretinoin) isotretinoin ZENATANE (isotretinoin)	ABSORICA (isotretinoin) ABSORICA LD (isotretinoin, micronized)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. Class only covered up to 20 years old; use in older patients is considered cosmetic.
TOPICAL		Review Schedule 1st Quarter
adapalene 0.3% gel/gel pump RX adapalene/benzoyl peroxide benzoyl peroxide clindamycin gel, lotion, solution, swab clindamycin/benzoyl peroxide gel 1.2/5% (generic DUAC) erythromycin gel, solution tretinoin cream tretinoin 0.01 %, 0.025% gel	adapalene 0.1% cream, 0.1% gel OTC AKLIEF (trifarotene) AVAR (sulfacetamide sodium/sulfur) BP 10-1 (sulfacetamide sodium/sulfur) BPO (benzoyl peroxide) CLEOCIN T (clindamycin) CLINDACIN ETZ/PAC (clindamycin) CLINDACIN P (clindamycin) clindamycin foam clindamycin/benzoyl peroxide gel 1/5% (generic BENZACLIN), 1.5/2.5% (generic ACANYA), 1.2/3.75% (generic ONEXTON) clindamycin/tretinoin dapson DIFFERIN (adapalene) EPIDUO (adapalene/benzoyl peroxide) EPIDUO FORTE (adapalene/benzoyl peroxide) ERY (erythromycin) erythromycin swab erythromycin/benzoyl peroxide EVOCLIN (clindamycin) FABIOR (tazarotene) LINTERA (benzoyl peroxide) NEUAC (benzoyl peroxide/clindamycin) sodium sulfacetamide/sulfur SSS (sulfacetamide sodium/sulfur) sulfacetamide sodium SUMADAN (sulfacetamide sodium/sulfur) SUMADAN XLT (sulfacetamide sodium/sulfur) SUMAXIN (sulfacetamide sodium/sulfur) tazarotene foam tretinoin 0.05% gel tretinoin microsphere TWYNEO (tretinoin/benzoyl peroxide) WINLEVI (clascoterone) ZMA CLEAR (sulfacetamide sodium/sulfur)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. Class only covered up to 20 years old; use in older patients is considered cosmetic.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
ANALGESICS		
ANALGESICS, NARCOTIC LONG-ACTING (Clinical criteria applies to class. All agents require a prior authorization.)		Review Schedule: 1st Quarter
BUTRANS (buprenorphine) fentanyl transdermal 12, 25, 50, 75, 100 mcg/hr morphine ER tablet tramadol ER tablet *	BELBUCA (buprenorphine buccal film) buprenorphine patch CONZIP (tramadol) fentanyl transdermal 37.5, 62.5, 87.5 mcg/hr hydrocodone ER hydromorphone ER HYSINGLA ER (hydrocodone) morphine ER capsule MS CONTIN (morphine) oxycodone ER OXYCONTIN (oxycodone) oxymorphone ER tapentadol ER tramadol ER capsule *	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. DMMA recommends that first fill of new pain medication be limited to 15-day supply. * Tramadol quantity limits – 240 units per 30 days
ANALGESICS, NARCOTIC SHORT-ACTING, NON-INJECTABLE		Review Schedule: 2nd Quarter
acetaminophen/codeine butalbital/ASA/caffeine/codeine #3 butalbital/acetaminophen/caffeine/codeine butalbital compound/codeine codeine ENDOCET (oxycodone/acetaminophen) hydrocodone/APAP solution, tablet hydromorphone tablet morphine concentrate, tablet, solution oxycodone capsule, solution, tablet oxycodone/APAP tablet tramadol 50 mg tablet * tramadol/APAP *	ACTIQ (fentanyl) buccal butorphanol nasal spray dihydrocodeine/APAP/caffeine DILAUDID (hydromorphone) FIORICET-CODEINE (butalbital/acetaminophen/caffeine/codeine) hydrocodone/ibuprofen hydromorphone liquid, suppository levorphanol meperidine solution, tablet morphine suppository NALOCET (oxycodone/acetaminophen) oxycodone concentrate oxycodone/ASA oxymorphone pentazocine HCl/naloxone HCl PERCOCET (oxycodone/acetaminophen) PROLATE (oxycodone/acetaminophen) ROXICODONE (oxycodone) ROXYBOND (oxycodone) tapentadol tramadol 25 mg, 75 mg [^] , 100 mg tablet, solution * XYVONA (levorphanol)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. DMMA recommends that first fill of new pain medication be limited to 7-day supply. [^] PA required, to include reason tramadol 50 mg tablet, cannot be used, before product will be approved. <p>QUANTITY LIMITS IN PLACE:</p> <ul style="list-style-type: none"> Oxycodone 15 mg maximum of 240 units per year Oxycodone 20 mg maximum of 120 units per year Oxycodone 30 mg maximum of 60 units per year 120 short-acting units per 30 days with a total of 720 short-acting units per year * Tramadol quantity limits – 240 units per 30 days

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
ANALGESICS, NON-NARCOTIC SHORT-ACTING		Review Schedule: 2nd Quarter
JOURNAVX (suzetrigine)		
ANTIHYPURICEMICS, ORAL		Review Schedule: 2nd Quarter
allopurinol 100 mg, 300 mg tablet colchicine tablet febuxostat probenecid probenecid with colchicine	allopurinol 200 mg tablet * colchicine capsule COLCRYS (colchicine) GLOPERBA (colchicine) LODOCO (colchicine) ** MITIGARE (colchicine) ULORIC (febuxostat)	<ul style="list-style-type: none"> • Two (2) preferred products required before a non-preferred product will be approved. • * PA required, to include reason allopurinol 2 x 100 mg tablets cannot be used, before product will be approved. • ** Step through preferred colchicine product required.
ANTIMIGRAINE AGENTS, PROPHYLAXIS (Clinical criteria applies to individual agents in class.)		Review Schedule: 4th Quarter
AIMOVIG (erenumab-aooe) * AJOVY (fremanezumab) * EMGALITY (galcanezumab-gnlm) 120 mg pen/syringe* QULIPTA (atogepant) **	BOTOX (onabotulinumtoxinA) EMGALITY (galcanezumab) 100 mg syringe * NURTEC ODT (rimegepant) *** VYEPTI (eptinezumab-jjmr)	<ul style="list-style-type: none"> • Two (2) preferred products required before a non-preferred product will be approved. • * Product will be approved. for patients with chronic migraine with inadequate response to two (2) preferred anti-migraine agents (acute and/or prophylaxis). • ** One (1) injectable CGRP receptor antagonist required before product will be approved. • *** Two (2) preferred products, one of which must be Qulipta, required before a product will be approved. <p>Abbreviation: CGRP = calcitonin gene-related peptide</p>
ANTIMIGRAINE AGENTS, TREATMENT (Clinical criteria applies to individual agents in class.)		Review Schedule: 4th Quarter
naratriptan rizatriptan ODT, tablet sumatriptan nasal spray, syringe, tablet, vial UBRELVY (ubrogepant) * zolmitriptan ODT, tablet	almotriptan BREKIYA (dihydroergotamine) dihydroergotamine eletriptan ERGOMAR (ergotamine tartrate) FROVA (frovatriptan) frovatriptan IMITREX (sumatriptan) MAXALT (rizatriptan) MIGERGOT (ergotamine tartrate/caffeine) MIGRANAL (dihydroergotamine mesylate)	<ul style="list-style-type: none"> • Two (2) preferred products required before a non-preferred product will be approved. • Quantity limits on Triptans and CGRP antagonists – 9 units per 45 days • * Ubrelyv will be approved. for patients failing a trial of two preferred triptans or for patients with contraindications to triptans. • ** Two (2) preferred products, one of which must be Ubrelyv, required before a product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
	NURTEC ODT (rimegepant) ** RELPAX (eletriptan) REYVOW (lasmiditan) sumatriptan cartridge, pen injector sumatriptan/naproxen SYMBRAVO (rizatriptan/meloxicam) *** TOSYMRA (sumatriptan) ZAVZPRET (zavegepant) ZEMBRACE (sumatriptan) zolmitriptan nasal spray ZOMIG (zolmitriptan)	<ul style="list-style-type: none"> *** PA required, to include reason separate ingredients cannot be used concurrently, before product will be approved
CYTOKINE AND CAM ANTAGONISTS, ORAL/SUBCUTANEOUS (Clinical criteria applies to class. All agents require a prior authorization.)		Review Schedule: 4th Quarter
adalimumab-adaz AVSOLA (infliximab-axxq) ENBREL (etanercept) ENTYVIO (vedolizumab) HADLIMA (adalimumab-bwwd) HUMIRA (adalimumab) infliximab KINERET (anakinra) ORENCIA (abatacept) OTEZLA (apremilast) 30 mg tablet, starter pack PYZCHIVA (ustekinumab-ttwe) RINVOQ (upadactinib) TALTZ (ixekizumab) TYENNE (tocilizumab) XELJANZ IR (tofacitinib) XELJANZ XR (tofacitinib) 11 mg tablet	ABRILADA (adalimumab-afzb) ACTEMRA (tocilizumab) adalimumab-aacf adalimumab-adbm adalimumab-fkjp adalimumab-ryvk AMJEVITA (adalimumab-atto) ARCALYST (rilonacept) AVTOZMA (tocilizumab-anoh) BIMZELX (bimekizumab-bkzx) CIMZIA (certolizumab pegol) COSENTYX (secukinumab) CYLTEZO (adalimumab-adbm) HULIO (adalimumab-fkjp) HYRIMOZ (adalimumab-adaz) ICOTYDE (icotrokinra) ILARIS (canakinumab) ILUMYA (tildrakizumab-asmn) IMULDOSA (ustekinumab-srlf) INFLECTRA (infliximab-dyyb) KEVZARA (sarilumab) LEQSELVI (deuruxolitinib) LITFULO (ritlecitinib) OLUMIANT (baricitinib) OMVOH (mirikizumab-mrkz) OTEZLA (apremilast) 20 mg tablet, starter pack OTEZLA XR (apremilast) OTULFI (ustekinumab -aauz) REMICADE (infliximab) RENFLEXIS (infliximab-abdb) RINVOQ LQ (upadactinib) SELARSDI (ustekinumab-aekn) SIMLANDI (adalimumab-ryvk) SIMPONI (golimumab) SIMPONI ARIA (golimumab) SKYRIZI (risankizumab-rzaa)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
	SOTYKTU (deucravacitinib) SPEVIGO (spesolimab-sbzo) STARJEMZA (ustekinumab-hmny) STELARA (ustekinumab) STEQEYMA (ustekinumab-stba) TOFIDENCE (tocilizumab) TREMFYA (guselkumab) ustekinumab ustekinumab-aaaz ustekinumab-aekn ustekinumab-ttwe VELSIPITY (etrasimod arginine) XELJANZ (tofacitinib) solution XELJANZ XR (tofacitinib) 22 mg tablet YESINTEK (ustekinumab-kfce) YUFLYMA (adalimumab-aaty) YUSIMRY (adalimumab-aqvh) ZYMFENTRA (infliximab-dyyb)	
NSAIDs, NASAL/ORAL/TOPICAL (Clinical criteria applies to individual agents in class.)		Review Schedule: 3rd Quarter
celecoxib diclofenac sodium 1.5% solution drops, 1% gel OTC, tablet ibuprofen (except 300 mg tablet) indomethacin capsule ketorolac tablet ** meloxicam tablet nabumetone naproxen IR tablet sulindac	ARTHROTEC (diclofenac sodium/misoprostol) CATAFLAM (diclofenac potassium) CELEBREX (celecoxib) DAYPRO (oxaprozin) diclofenac epolamine patch diclofenac potassium diclofenac sodium 1% gel RX, 2% solution pump diclofenac/misoprostol diflunisal DOLOBID (diflunisal) * etodolac ELYXYB (celecoxib) fenoprofen flurbiprofen ibuprofen 300 mg tablet ibuprofen/famotidine indomethacin suppository, suspension INDOCIN (indomethacin) ketoprofen ketoprofen ER ketorolac vial *** LOFENA (diclofenac potassium) LURBIRO (flurbiprofen) meclofenamate mefenamic acid meloxicam capsule NALFON (fenoprofen) NAPRELAN (naproxen) naproxen DR, suspension	<ul style="list-style-type: none"> • Two (2) preferred products required before a non-preferred product will be approved. • * Five (5) preferred products required before Dolobid will be approved. • ** PA required, to include reason 2 x 500 mg nabumetone tablets cannot be used, before product will be approved. • *** Quantity limits on ketorolac – 20 units per 30 days • ^ PA required, to include reason meloxicam tablet cannot be used, before product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
	naproxen/esomeprazole naproxen sodium ORUDIS (ketoprofen) oxaprozin PENNSAID (diclofenac) piroxicam RELAFEN (nabumetone) RELAFEN DS (nabumetone) ** tolmetin VOLTAREN (diclofenac sodium) 1% GEL VYSCOXA (celecoxib) ZYBIC (meloxicam) ^	
OPIATE DEPENDENCE TREATMENTS		Review Schedule: 4th Quarter
BRIXADI (buprenorphine) buprenorphine buprenorphine/naloxone naltrexone SUBLOCADE (buprenorphine) VIVITROL (naltrexone)	lofexidine LUCEMYRA (lofexidine) SUBOXONE films (buprenorphine/naloxone) ZUBSOLV (buprenorphine/naloxone)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
ANTIDOTES		
CHELATING AGENTS		Review Schedule: 4th Quarter
deferasirox granules *, tablet	deferasirox ODT deferiprone EXJADE (deferasirox) FERRIPROX (deferiprone) JADENU (deferasirox)	<ul style="list-style-type: none"> One (1) preferred product required before a non-preferred product will be approved. * Requires prior authorization for members ≥ 10-years old
OPIATE OVERDOSE TREATMENTS		Review Schedule: 4th Quarter
KLOXXADO (naloxone) naloxone injection naloxone nasal spray RX, OTC NARCAN nasal spray OTC (naloxone)	nalmefene injection NARCAN nasal spray RX (naloxone) OPVEE (nalmefene) REXTOVY (naloxone) ZIMHI (naloxone hydrochloride) ZURNAL (nalmefene)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
ANTI-INFECTIVE AGENTS		
ANTIBIOTICS, GI (Clinical criteria applies to individual agents in class.)		Review Schedule: 4th Quarter
metronidazole 250 mg, 500 mg tablet neomycin	DIFICID (fidaxomicin) * fidaxomicin *	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
tinidazole vancomycin capsule, solution	FIRVANQ (vancomycin) LIKMEZ (metronidazole) metronidazole capsule **, 125 mg tablet nitazoxanide tablet VANCOCIN (vancomycin) VOWST (fecal microbiota spores, live-brpk)	<ul style="list-style-type: none"> * Step through one (1) preferred vancomycin product required before product will be approved. ** PA required, to include reason metronidazole 250 mg tablet cannot be used, before product will be approved.
ANTIBIOTICS, INHALED		Review Schedule: 4th Quarter
tobramycin 300 mg/5 mL (gen TOBI PODHALER)	ARIKAYCE (amikacin) BETHKIS (tobramycin) CAYSTON (aztreonam) KITABIS PAK (tobramycin) TOBI PODHALER (tobramycin) tobramycin 300 mg/4 mL tobramycin 300 mg/5 mL (gen KITABIS PAK)	<ul style="list-style-type: none"> One (1) preferred product required before a non-preferred product will be approved.
ANTIBIOTICS, VAGINAL		Review Schedule: 4th Quarter
CLEOCIN ovules (clindamycin) clindamycin metronidazole 0.75% gel NUVESSA (metronidazole)	CLINDESSE (clindamycin) metronidazole 1.3% gel SOLOSEC (secnidazole) VANDAZOLE (metronidazole) XACIATO (clindamycin)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
ANTIFUNGALS, ORAL		Review Schedule: 4th Quarter
clotrimazole fluconazole griseofulvin suspension nystatin terbinafine	CRESEMBA (isavuconazonium) DIFLUCAN (fluconazole) flucytosine griseofulvin tablet itraconazole ketoconazole NOXAFIL (posaconazole) suspension, PowderMix ORAVIG (miconazole) posaconazole SPORANOX (itraconazole) TOLSURA (itraconazole) VFEND (voriconazole) VIVJOA (oteseconazole) voriconazole	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
ANTIVIRALS, ANTIRETROVIRALS		Review Schedule: 4th Quarter
abacavir abacavir/lamivudine APRETUDE (cabotegravir extended-release) atazanavir BIKTARVY (bictegravir/emtricitabine/	abacavir/lamivudine/zidovudine APTIVUS (tipranavir) CIMDUO (lamivudine/tenofovir) darunavir EDURANT tablet (rilpivirine)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. * Requires prior authorization for members ≥ 10-years old

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
tenofovir AF) CABENUVA (cabotegravir/rilpivirine) COMPLERA (emtricitabine/rilpivirine/tenofovir) DELSTRIGO (doravirine/lamivudine/tenofovir) darunavir DESCOVY (emtricitabine/tenofovir AF) DOVATO (dolutegravir/lamivudine) EDURANT tablet for suspension (rilpivirine) * efavirenz efavirenz-emtricitabine-tenofovir emtricitabine emtricitabine-tenofovir disoproxil fumarate EVOTAZ (atazanavir/cobicistat) GENVOYA (elvitegravir/cobicistat/emtricitabine/tenofovir AF) ISENTRESS (raltegravir potassium) lamivudine lamivudine-zidovudine lopinavir-ritonavir nevirapine ODEFSEY (emtricitabine/rilpivirine/tenofovir AF) PIFELTRO (doravirine) PREZCOBIX (darunavir/cobicistat) RETROVIR injection (zidovudine) REYATAZ powder pack (atazanavir) rilpivirine tablet ritonavir SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir AF) tenofovir disoproxil fumarate TIVICAY (dolutegravir sodium) TIVICAY PD (dolutegravir sodium) TRIUMEQ (abacavir/lamivudine/dolutegravir) TRIUMEQ PD (abacavir/lamivudine/dolutegravir) TYBOST (cobicistat) YEZTUGO (lenacapavir) zidovudine	efavirenz/lamivudine/tenofovir emtricitabine/rilpivirine/tenofovir EMTRIVA (emtricitabine) EPIVIR (lamivudine) EPZICOM (abacavir/lamivudine) etravirine fosamprenavir FUZEON (enfuvirtide) INTELENCE (etravirine) ISENTRESS HD (raltegravir potassium) JULUCA (dolutegravir/rilpivirine) KALETRA (lopinavir/ritonavir) maraviroc nevirapine ER NORVIR (ritonavir) PREZISTA (darunavir) RUKOBIA (fostemsavir) SELZENTRY (maraviroc) STRIBILD (elvitegravir/cobicistat/emtricitabine/tenofovir) SUNLENCA (lenacapavir) SYMFI (efavirenz/lamivudine/tenofovir) TROGARZO (ibalizumab-uiyk) TRUVADA (emtricitabine/tenofovir DF) VIRACEPT (nelfinavir mesylate) VIREAD (tenofovir disoproxil fumarate) ZIAGEN (abacavir)	
ANTIVIRALS, COVID - 19		Review Schedule: 4th Quarter
PAXLOVID (nirmatrelvir/ritonavir)	LAGEVRIO (molnupiravir)	<ul style="list-style-type: none"> One (1) preferred product required before a non-preferred product will be approved.
ANTIVIRALS, HEPATITIS C AGENTS		Review Schedule: 4th Quarter
MAVYRET (glecaprevir/pibrentasvir) ribavirin sofosbuvir/velpatasvir	EPCLUSA (sofosbuvir/velpatasvir) pellet pack, tablet HARVONI (ledipasvir/sofosbuvir) ledipasvir/sofosbuvir PEGASYS (peginterferon alfa-2a) SOVALDI (sofosbuvir)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. Limited to one treatment cycle every 365 days

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
	VOSEVI (sofosbuvir/velpatasvir/voxilaprevir) ZEPATIER (elbasvir/grazoprevir)	
ANTIVIRALS, ORAL/INHALATION		Review Schedule: 4th Quarter
acyclovir amantadine capsule, solution famciclovir oseltamivir * valacyclovir valganciclovir	amantadine tablet LIVTENCITY (maribavir) PREVYMIS (letermovir) RELENZA (zanamivir) * rimantadine SITAVIG (acyclovir) TAMIFLU (oseltamivir) * VALCYTE (valganciclovir) VALTREX (valacyclovir) XOFLUZA (baloxavir marboxil)	<ul style="list-style-type: none"> • Two (2) preferred products required before a non-preferred product will be approved. • Liquid medications require prior authorization for members ≥ 10-years old • * Quantity limits in place for oseltamivir and RELENZA
CEPHALOSPORINS, ORAL		Review Schedule: 3rd Quarter
cefaclor IR capsule cefadroxil capsule cefdinir cefprozil cefuroxime cephalexin 250 mg, 500 mg capsule, suspension	cefaclor ER tablet cefaclor suspension cefadroxil suspension, tablet cefixime cefopodoxime cephalexin 750 mg capsule, tablet	<ul style="list-style-type: none"> • Two (2) preferred products required before a non-preferred product will be approved.
FLUOROQUINOLONES, ORAL		Review Schedule: 3rd Quarter
ciprofloxacin IR tablet levofloxacin tablet	BAXDELA (delafloxacin) CIPRO (ciprofloxacin) ciprofloxacin ER ciprofloxacin suspension levofloxacin solution moxifloxacin ofloxacin	<ul style="list-style-type: none"> • Two (2) preferred products required before a non-preferred product will be approved.
LINCOSAMIDES/OXAZOLIDINONES/STREPTOGRAMINS (Clinical criteria applies to individual agents in class.)		Review Schedule: 2nd Quarter
clindamycin capsule clindamycin solution	CLEOCIN (clindamycin) linezolid * SIVEXTRO (tedizolid) * ZYVOX (linezolid) *	<ul style="list-style-type: none"> • One (1) preferred product required before a non-preferred product will be approved. • * Clinical criteria applies

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
MACROLIDES Review Schedule: 4th Quarter		
azithromycin clarithromycin tablet erythromycin suspension	clarithromycin suspension clarithromycin ER E.E.S. 400 ERY-TAB (erythromycin) ERYPED (erythromycin ethylsuccinate) ERYTHROCIN (erythromycin stearate) erythromycin (all other salts/formulations) ZITHROMAX (azithromycin)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
PENICILLINS, ORAL/IM Review Schedule: 3rd Quarter		
amoxicillin amoxicillin/clavulanate (except 250 mg suspension, tablet) ampicillin BICILLIN C-R BICILLIN L-A dicloxacillin penicillin penicillin G procaine	amoxicillin/clavulanate 250 mg suspension, tablet amoxicillin/clavulanate XR AUGMENTIN (amoxicillin/potassium clavulanate) AUGMENTIN ES (amoxicillin/potassium clavulanate)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
TETRACYCLINES Review Schedule: 4th Quarter		
doxycycline hyclate 20, 100 mg tablet doxycycline hyclate capsule doxycycline monohydrate 50, 100 mg capsule doxycycline monohydrate tablet minocycline capsule	demeclocycline DORYX (doxycycline hyclate) doxycycline DR doxycycline hyclate 50, 75, 150 mg tablet doxycycline monohydrate 75, 150 mg capsule doxycycline suspension minocycline ER minocycline tablet NUZYRA (omadacycline) TARGADOX (doxycycline hyclate) tetracycline XIMINO (minocycline)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
URINARY ANTI-INFECTIVES Review Schedule: 1st Quarter		
methenamine hippurate methenamine mandelate nitrofurantoin macrocrystals (generic MACRODANTIN) nitrofurantoin monohydrate-macrocrystals (generic MACROBID)	BLUJEP (gepotidacin) fosfomycin tromethamine MACROBID (nitrofurantoin monohydrate-macrocrystals) nitrofurantoin suspension ORLYNVAH (sulopenem etzadroxil/probenecid) PIVYA (pivmecillinam)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
ANTINEOPLASTICS		
ONCOLOGY AGENTS (Clinical criteria apply to individual agents in class.)		Review Schedule: 3rd Quarter
all other drug products	AFINITOR (everolimus) AFINITOR DISPERZ (everolimus) ALKERAN (melphalan) CASODEX (bicalutamide) CYTOXAN (cyclophosphamide) DANZITEN (nilotinib) * dasatinib EULEXIN (flutamide) FARESTON (toremifene) GILOTRIF (afatinib) GLEEVEC (imatinib) GLEOSTINE (lomustine) HYDREA (hydroxyurea) INLYTA (axitinib) IRESSA (gefitinib) MESNEX (mesna) NEXAVAR (sorafenib) nilotinib HCl (generic Tasigna) nilotinib tartrate * NOLVADEX (tamoxifen) POMALYST (pomalidomide) PURINETHOL (mercaptopurine) REVLIMID (lenalidomide) SPRYCEL (dasatinib) SUTENT (sunitinib) TEMODAR (temozolomide) THALOMID (thalidomide) TYKERB (lapatinib) VOTRIENT (pazopanib) XELODA (capecitabine) ZORTRESS (everolimus) ZYTIGA (abiraterone acetate)	<ul style="list-style-type: none"> Effective January 1, 2025, any member starting a new prescription for an oral oncology medication with an AB-rated generic must attempt a 30-day supply of the generic before brand name medications will be considered, unless the brand name medication is on the Brand over Generic (BoG) list. This change does NOT impact those currently on oral oncology medications. For brand-name medications not on the BoG list to be considered, providers must submit a prior authorization form with documentation of medical trial of the generic and outcome electronically via the DMAP Provider Portal. Please refer to the Delaware Pharmacy Corner website for the BoG list. https://medicaid.dhss.delaware.gov/provider/Home/PharmacyCornerLanding/tabid/2096/Default.aspx * PA required, to include reason Tasigna cannot be used, before product will be approved.
CARDIOVASCULAR AGENTS		
ANGIOTENSIN MODULATORS		Review Schedule: 1st Quarter
benazepril benazepril/HCTZ enalapril enalapril/HCTZ fosinopril irbesartan irbesartan/HCTZ	ACCUPRIL (quinapril) ACCURETIC (quinapril/HCTZ) aliskerin ALTACE (ramipril) ATACAND (candesartan) ATACAND HCT (candesartan/HCTZ) AVALIDE (irbesartan/HCTZ)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. Dose optimization required when applicable.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
lisinopril lisinopril/HCTZ losartan losartan/HCTZ olmesartan olmesartan/HCTZ quinapril quinapril/HCTZ ramipril trandolapril valsartan tablet valsartan/HCTZ	AVAPRO (irbesartan) BENICAR (olmesartan) BENICAR HCT (olmesartan/HCTZ) candesartan candesartan/HCTZ captopril captopril/HCTZ COZAAR (losartan) DIOVAN (valsartan) DIOVAN HCT (valsartan/HCTZ) EDARBI (azilsartan) EDARBYCLOR (azilsartan/chlorthalidone) EPANED (enalapril) eprosartan fosinopril/HCTZ HYZAAR (losartan/HCTZ) LOTENSIN (benazepril) LOTENSIN HCT (benazepril/HCTZ) MICARDIS (telmisartan) MICARDIS HCT (telmisartan/HCTZ) moexipril perindopril QBRELIS (lisinopril) TEKTURNA (aliskiren) telmisartan telmisartan/HCTZ valsartan solution ZESTORETIC (lisinopril/HCTZ) ZESTRIL (lisinopril)	
ANGIOTENSIN MODULATOR/CALCIUM CHANNEL BLOCKER COMBINATIONS		Review Schedule: 1st Quarter
amlodipine/benazepril amlodipine/valsartan amlodipine/valsartan/ HCTZ olmesartan/amlodipine olmesartan/amlodipine/HCTZ	AZOR (amlodipine/olmesartan) EXFORGE (amlodipine/valsartan) EXFORGE HCT (amlodipine/valsartan/HCTZ) LOTREL (amlodipine/benazepril) telmisartan/amlodipine trandolapril/verapamil TRIBENZOR (olmesartan/amlodipine/HCTZ)	<ul style="list-style-type: none"> • Two (2) preferred products required before a non-preferred product will be approved. • Dose optimization required when applicable.
ANTIHYPERTENSIVES, SYMPATHOLYTIC		Review Schedule: 1st Quarter
clonidine patch, IR tablet doxazosin guanfacine methyl dopa prazosin terazosin	CARDURA (doxazosin) clonidine ER (generic NEXICLON XR) JAVADIN (clonidine) * MINIPRESS (prazosin) NEXICLON XR (clonidine) TEZRULY (terazosin) **	<ul style="list-style-type: none"> • Two (2) preferred products required before a non-preferred product will be approved. • * PA required, to include reason preferred clonidine product cannot be used, before product will be approved • ** PA required, to include reason terazosin capsule cannot be used, before product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
BETA BLOCKERS Review Schedule: 2nd Quarter		
atenolol atenolol/chlorthalidone bisoprolol 5 mg, 10 mg tablet bisoprolol/HCTZ carvedilol IR labetalol 100 mg, 200 mg, 300 mg tablet metoprolol IR (except 12.5 mg) metoprolol ER nadolol nebivolol propranolol propranolol ER sotalol	acebutolol BETAPACE (sotalol) betaxolol bisoprolol 2.5 mg tablet BYSTOLIC (nebivolol) carvedilol ER HEMANGEOL (propranolol) INDERAL LA (propranolol) INDERAL XL (propranolol) INNOPRAN XL (propranolol) KAPSPARGO (metoprolol) labetalol 400 mg tablet* LOPRESSOR (metoprolol) solution **, tablet LOPRESSOR HCT (metoprolol/HCTZ) metoprolol 12.5 mg tablet *** metoprolol/HCTZ pindolol SOTYLIZE (sotalol) TENORETIC (atenolol/chlorthalidone) TENORMIN (atenolol) timolol TOPROL XL (metoprolol ER) ZIAC (bisoprolol/HCTZ)	<ul style="list-style-type: none"> • Two (2) preferred products required before a non-preferred product will be approved. • * PA required, to include reason labetalol 2 x 200 mg tablets cannot be used, before product will be approved. • ** PA required, to include reason preferred metoprolol product and propranolol solution cannot be used, before product will be approved. • *** PA required, to include reason preferred metoprolol 25 mg tablet cannot be used, before product will be approved.
CALCIUM CHANNEL BLOCKERS Review Schedule: 3rd Quarter		
amlodipine CARTIA XT (diltiazem ER) DILT-XR (diltiazem ER) diltiazem ER capsule diltiazem IR felodipine nifedipine ER nifedipine IR nimodipine * TAZTIA XT (diltiazem ER) TIADYLT ER (diltiazem ER) verapamil ER tablet, capsule verapamil IR	CARDAMYST (etripamil) diltiazem ER tablet isradipine KATERZIA (amlodipine) levamlodipine maleate MATZIM LA (diltiazem ER) nicardipine nisoldipine ER NORLIQVA (amlodipine) NORVASC (amlodipine) NYMALIZE (nimodipine) PROCARDIA (nifedipine) PROCARDIA XL (nifedipine ER) SDAMLO (amlodipine) ** SULAR (nisoldipine) verapamil ER PM verapamil SR pellet	<ul style="list-style-type: none"> • Two (2) preferred products required before a non-preferred product will be approved. • Dose optimization required when applicable. • * ICD-10 code for SAH may create system-generated approval for nimodipine. • ** PA required, to include reason preferred amlodipine product cannot be used, before product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
DIURETICS Review Schedule: 1st Quarter		
acetazolamide tablet acetazolamide ER capsule amiloride amiloride/HCTZ bumetanide chlorothiazide chlorthalidone furosemide hydrochlorothiazide (HCTZ) indapamide metolazone spironolactone spironolactone/HCTZ torsemide triamterene/HCTZ	ALDACTAZIDE (spironolactone/HCTZ) ALDACTONE (spironolactone) CAROSPIR (spironolactone) dichlorphenamide ENBUMYST (bumetanide) eplerenone ** ethacrynic acid HEMICLOR (chlorthalidone) * INSPRA (eplerenone) ** INZIRQO (HCTZ) KERENDIA (finerenone) ** KEVEYIS (dichlorphenamide) LASIX (furosemide) LASIX ONYU (furosemide) MAXZIDE (triamterene/HCTZ) methazolamide THALITONE (chlorthalidone) triamterene	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. * PA required, to include reason chlorthalidone 25 mg tablet cannot be used, before product will be approved. ** Two (2) preferred products, one (1) of which must be a preferred spironolactone product, required before a non-preferred product will be approved.
EPINEPHRINE, SELF-INJECTED Review Schedule: 4th Quarter		
epinephrine auto-injector AG (Mylan Specialty – labeler 49502)	AUVI-Q (epinephrine) EPI-PEN (epinephrine) epinephrine auto-injector (other than Mylan Specialty – labeler 49502) NEFFY (epinephrine)	<ul style="list-style-type: none"> One (1) preferred product required before a non-preferred product will be approved.
HEART FAILURE DRUGS Review Schedule: 4th Quarter		
sacubitril /valsartan tablet	ENTRESTO (sacubitril /valsartan) TABLET INPEFA (sotagliflozin) VERQUVO (vericiguat) ENTRESTO (sacubitril /valsartan) SPRINKLE	<ul style="list-style-type: none"> One (1) preferred product required before a non-preferred product will be approved.
LIPOTROPICS, OTHER (Clinical criteria applies to individual agents in class.) Review Schedule: 4th Quarter		
cholestyramine cholestyramine light colessevalam tablet colestipol ezetimibe fenofibrate (gen LOFIBRA) fenofibrate (gen TRICOR) gemfibrozil niacin ER RX omega-3 acid ethyl esters PRALUENT (alirocumab) *	ANTARA (fenofibrate) colesevalam powder COLESTID (colestipol) EVKEEZA (evinacumab-dgnb) ezetimibe/simvastatin fenofibrate (gen FENOGLIDE) fenofibrate (gen LIPOFEN) fenofibric acid (gen FIBRICOR) fenofibric acid (gen TRILIPIX) FENOGLIDE (fenofibrate) icosapent ethyl	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. * Clinical criteria applies

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
PREVALITE (cholestyramine) POWDER, POWDER PACK REPATHA (evolocumab) *	JUXTAPID (lomitapide) LEQVIO (inclisiran) LIPOFEN (fenofibrate) LOPID (gemfibrozil) NEXLETOL (bempedoic acid) NEXLIZET (bempedoic acid/ezetimibe) NIASPAN (niacin) REDEMPLO (plozasiran) * TRICOR (fenofibrate) TRYNGOLZA (olesarzen) * VYTORIN (ezetimibe/simvastatin) WELCHOL (colesevelam) ZETIA (ezetimibe)	
LIPOTROPICS, STATINS		Review Schedule: 2nd Quarter
atorvastatin lovastatin pravastatin rosuvastatin simvastatin	ALTOPREV (lovastatin) amlodipine/atorvastatin ATORVALIQ (atorvastatin) suspension CADUET (amlodipine/atorvastatin) CRESTOR (rosuvastatin) fluvastatin fluvastatin ER LESCOL XL (fluvastatin) LIPITOR (atorvastatin) LIVALO (pitavastatin) ZOCOR (simvastatin) ZYPITAMAG (pitavastatin)	<ul style="list-style-type: none"> • Two (2) preferred products required before a non-preferred product will be approved. • Once daily dosing required.
PAH AGENTS, ORAL & INHALED (Clinical criteria applies to class. All agents require a prior authorization.)		Review Schedule: 4th Quarter
ambrisentan bosentan tablet sildenafil 20 mg tablet sildenafil 10 mg/mL suspension * tadalafil 20 mg tablet (generic ADCIRCA)	ADCIRCA (tadalafil) ADEMPAS (riociguat) ALYQ (tadalafil) bosentan soluble tablet LETAIRIS (ambrisentan) OPSUMIT (macitentan) OPSYNVI (macitentan/tadalafil) ORENITRAM ER (treprostinil) REVATIO (sildenafil) TADLIQ (tadalafil) suspension TRACLEER (bosentan) treprostinil TYVASO DPI (treprostinil) UPTRAVI (selexipag) WINREVAIR (sotatercept) YUTREPIA (treprostinil)	<ul style="list-style-type: none"> • Two (2) preferred products required before a non-preferred product will be approved. • * PA required, to include reason sildenafil tablet cannot be used, if member is ≥ 10-years old.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
VASODILATORS, CORONARY Review Schedule: 1st Quarter		
isosorbide dinitrate isosorbide mononitrate isosorbide mononitrate ER nitroglycerin patch, tablet ranolazine ER	ASPRUZYO (ranolazine) BIDIL (isosorbide dinitrate/hydralazine) GONITRO (nitroglycerin) isosorbide dinitrate/hydralazine NITRO-BID (nitroglycerin) ointment NITRO-DUR (nitroglycerin) patch nitroglycerin ointment, translingual spray NITROLINGUAL (nitroglycerin) spray NITROMIST (nitroglycerin) NITROSTAT (nitroglycerin) tablet	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
CENTRAL NERVOUS SYSTEM DRUGS		
ANTIDEPRESSANTS, OTHER Review Schedule: 4th Quarter (Clinical criteria applies to individual agents in class.)		
amitriptyline bupropion IR bupropion SR bupropion XL 150, 300 mg clomipramine desvenlafaxine ER (gen PRISTIQ) doxepin duloxetine 20 mg, 30 mg, 60 mg imipramine HCl MARPLAN (isocarboxazid) mirtazapine tablet nortriptyline phenelzine SPRAVATO (esketamine) * tranylcypromine trazodone 50, 100, 150 mg venlafaxine ER capsule venlafaxine IR	amitriptyline/chlordiazepoxide amoxapine ANAFRANIL (clomipramine) AUVELITY (dextromethorphan HBr/bupropion) bupropion XL 450 mg CYMBALTA (duloxetine) desipramine desvenlafaxine ER 50 mg, 100 mg (unbranded) DRIZALMA (duloxetine) duloxetine 40 mg EFFEXOR XR (venlafaxine ER) CAPSULE EMSAM (selegiline) EXXUA ER (gepirone) FETZIMA (levomilnacipran) FORFIVO XL (bupropion) imipramine pamoate mirtazapine ODT NARDIL (phenelzine) nefazodone NORPRAMIN (desipramine) PAMELOR (nortriptyline) PRISTIQ (desvenlafaxine) protriptyline RALDESY (trazodone) REMERON (mirtazapine) REMERON SOLUTAB (mirtazapine) trazodone 300 mg trimipramine TRINTELLIX (vortioxetine) venlafaxine HCL ER tablet venlafaxine besylate ER VIIBRYD (vilazodone HCl)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. DMAP requires prior authorization for all antidepressants for patients under six (6) years of age. * Clinical criteria applies

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
	vilazodone ZURZUVAE (zuranolone)	
ANTIDEPRESSANTS, SSRIs		Review Schedule: 4th Quarter
citalopram solution, tablet escitalopram tablet fluoxetine capsule, solution fluvoxamine tablet paroxetine IR tablet sertraline concentrate, tablet	CELEXA (citalopram) citalopram capsule escitalopram capsule, solution * fluoxetine tablet fluoxetine DR fluvoxamine ER LEXAPRO (escitalopram) paroxetine CR, ER paroxetine capsule, suspension * PAXIL (paroxetine) PEXEVA (paroxetine) PROZAC (fluoxetine) sertraline capsule ZOLOFT (sertraline)	<ul style="list-style-type: none"> • Two (2) preferred products required before a non-preferred product will be approved. • DMAP requires prior authorization for all antidepressants for patients under six (6) years of age. • Liquid medications require prior authorization for members ≥ 10-years old. • * PA required, to include reason IR tablet formulations cannot be used, before product will be approved.
ANTIPSYCHOTICS, ORAL/INHALATION (Clinical criteria applies to individual agents in class.)		Review Schedule: 4th Quarter
amitriptyline/perphenazine aripiprazole solution, tablet clozapine haloperidol concentrate, solution, tablet loxapine lurasidone olanzapine tablet paliperidone ER perphenazine pimozide quetiapine quetiapine XR risperidone solution, tablet thioridazine thiothixene trifluoperazine VRAYLAR (cariprazine) ziprasidone	ABILIFY (aripiprazole) aripiprazole ODT asenapine sublingual tablet CAPLYTA (lumateperone) chlorpromazine clozapine ODT CLOZARIL (clozapine) COBENFY (xanomeline/trospium) FANAPT (iloperidone) fluphenazine GEODON (ziprasidone) capsule INVEGA (paliperidone) tablet LATUDA (lurasidone) LYBALVI (olanzapine/samidorphan) molindone NUPLAZID (pimavanserin tartrate) OPIPZA (aripiprazole) * olanzapine ODT olanzapine/fluoxetine REXULTI (brexpirazole) RISPERDAL (risperidone) risperidone ODT SAPHRIS (asenapine) SECUADO (asenapine) SEROQUEL (quetiapine) SEROQUEL XR (quetiapine) VERSACLOZ (clozapine)	<ul style="list-style-type: none"> • Two (2) preferred products required before a non-preferred product will be approved. • * Two (2) preferred products, one (1) of which must be aripiprazole solution, required before product will be approved. • PA required for all antipsychotics for patients under eighteen (18) years of age.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
	ZYPREXA (olanzapine) tablet	
ANTIPSYCHOTICS, INJECTABLE/INHALATION		Review Schedule: 4th Quarter
ABILIFY ASIMTUFI (aripiprazole) ABILIFY MAINTENA (aripiprazole) ARISTADA (aripiprazole) chlorpromazine fluphenazine fluphenazine decanoate haloperidol decanoate haloperidol lactate INVEGA HAFYERA (paliperidone) INVEGA SUSTENNA (paliperidone) INVEGA TRINZA (paliperidone) olanzapine RISPERDAL CONSTA (risperidone) UZEDY (risperidone) ziprasidone mesylate IM	ADASUVE (loxapine) ERZOFRI (paliperidone) GEODON IM (ziprasidone) PERSERIS (risperidone) risperidone ER vial RYKINDO (risperidone microspheres) ZYPREXA (olanzapine) ZYPREXA RELPREVV (olanzapine)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. PA required for all antipsychotics for patients under eighteen (18) years of age.
ANXIOLYTICS		Review Schedule: 2nd Quarter
buspirone chlordiazepoxide clorazepate diazepam solution, tablet hydroxyzine pamoate hydroxyzine HCl solution, tablet lorazepam tablet	alprazolam ER/XR, IR, intensol, ODT BUCAPSOL (buspirone) * diazepam intensol LIBRIUM (chlordiazepoxide) lorazepam intensol LOREEV XR (lorazepam) meprobamate oxazepam VALIUM (diazepam) XANAX (alprazolam) XANAX XR (alprazolam)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. * PA required, to include reason buspirone tablet cannot be used, before product will be approved. Quantity Limits of 120 units of benzodiazepines per 30 days
MOOD STABILIZERS		Review Schedule: 4th Quarter
carbamazepine 100 mg chewable tablet, tablet carbamazepine ER, XR carbamazepine suspension divalproex sodium lamotrigine IR lithium IR lithium ER SUBVENITE (lamotrigine) tablet valproic acid	carbamazepine 200 mg chewable tablet * DEPAKOTE (divalproex) DEPAKOTE ER (divalproex) LAMICTAL (lamotrigine) LAMICTAL ODT (lamotrigine) LAMICTAL XR (lamotrigine) lamotrigine ER, ODT LITHOBID (lithium) SUBVENITE (lamotrigine) solution ** TEGRETOL (carbamazepine) suspension, tablet TEGRETOL-XR (carbamazepine) TERIL (carbamazepine) suspension	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. * PA required, to include reason carbamazepine 2 x 100 mg chewable tablets cannot be used, before product will be approved. ** PA required, to include reason preferred lamotrigine agent cannot be used, before product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
SEDATIVE HYPNOTICS Review Schedule: 2nd Quarter		
temazepam 15mg, 30mg zaleplon zolpidem IR tablet	AMBIEN (zolpidem) AMBIEN CR (zolpidem) BELSOMRA (suvorexant) DAYVIGO (lemborexant) DORAL (quazepam) doxepin 3mg, 6 mg EDLUAR (zolpidem) estazolam eszopiclone flurazepam HALCION (triazolam) HETLIOZ (tasimelteon) capsule, suspension IGALMI (dexmedetomidine HCl) LUNESTA (eszopiclone) quazepam QUVIVIQ (daridorexant HCl) ramelteon RESTORIL (temazepam) ROZEREM (ramelteon) SILENOR (doxepin) SONATA (zaleplon) tasimelteon temazepam 7.5mg, 22.5mg triazolam zolpidem ER zolpidem IR capsule	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. Dose optimization required when applicable. Quantity limits – 30 units per 30 days
DIABETIC SUPPLY LIST		
Please refer to the Delaware Pharmacy Corner website for covered Diabetic Supply products. https://medicaid.dhss.delaware.gov/provider/Home/PharmacyCornerLanding/tabid/2096/Default.aspx		
ENDOCRINE AND METABOLIC DRUGS		
ANDROGENIC AGENTS Review Schedule: 4th Quarter (Clinical criteria applies to class. All agents require a prior authorization.)		
DEPO-TESTOSTERONE (testosterone cypionate) testosterone cypionate testosterone enanthate testosterone gel pump 20.25/1.25	ANDROID 25 (methyltestosterone) ANDROGEL (testosterone) AVEED (testosterone undecanoate) AZMIRO (testosterone cypionate) JATENZO (testosterone undecanoate) KYZATREX (testosterone undecanoate)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
	METHITEST (methyltestosterone) methyltestosterone NATESTO (testosterone) TESTIM (testosterone) testosterone gel (except preferred formulation) TLANDO (testosterone undecanoate) VOGELXO (testosterone) XYOSTED (testosterone enanthate)	
BONE RESORPTION SUPPRESSION AND RELATED AGENTS (Clinical criteria applies to individual agents in class)		Review Schedule: 4th Quarter
alendronate tablet calcitonin-salmon nasal spray ibandronate JUBBONTI (denosumab-bbdz) * raloxifene teriparatide * WYOST (denosumab-bbdz) *	ACTONEL (risedronate) alendronate solution ATELVIA (risedronate) AUKELSO (denosumab-kyqq) * BILDYOS (denosumab-nxxp) * BILPREVDA (denosumab-nxxp) * BINOSTO (alendronate) BOMYNTRA (denosumab-bnht) * BONSTY (teriparatide) * BOSAYA (denosumab-kyqq) * CONEXXENCE (denosumab-bnht) * ENOBY (denosumab-qbde) * EVENITY (romosozumab-aqqg) * EVISTA (raloxifene) FORTEO (teriparatide) * FOSAMAX (alendronate) FOSAMAX PLUS D (alendronate/vitamin D) NATPARA (parathyroid hormone) * OSENVILT (denosumab-bmwo) * PROLIA (denosumab) * risedronate STOBOCLO (denosumab-bmwo) * TYMLOS (abaloparatide) * XGEVA (denosumab) * XTRENBO (denosumab-qbde) * YORVIPATH (palopegteriparatide) *	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. * Clinical PA is required for injectable medications in this class
CONTRACEPTIVES, ORAL – BIPHASIC		Review Schedule: 1st Quarter
desogestrel-ethinyl estradiol-eth estradiol	LO LOESTRIN FE (norethindrone-ethinyl estradiol- FE)	<ul style="list-style-type: none"> One (1) preferred product required before a non-preferred product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
CONTRACEPTIVES, ORAL - COMBINATION Review Schedule: 1st Quarter		
BLISOVI FE (norethindrone-ethinyl estradiol-FE) CRYSELLE (norgestrel-ethinyl estradiol) desogestrel-ethinyl estradiol drospironone-ethinyl estradiol ENSKYCE (desogestrel-ethinyl estradiol) ethynodiol-ethinyl estradiol ICLEVIA (levonorgestrel-ethinyl estradiol) INTROVALE (levonorgestrel-ethinyl estradiol) levonorgestrel-ethinyl estradiol LUIZZA (norethindrone-ethinyl estradiol) MICROGESTIN (norethindrone-ethinyl estradiol) MICROGESTIN-FE (norethindrone-ethinyl estradiol-FE) norethindrone-ethinyl estradiol norethindrone-ethinyl estradiol-FE tablet, capsule, chewable norgestimate-ethinyl estradiol norgestrel-ethinyl estradiol OCELLA (drospironone-ethinyl estradiol) SETLAKIN (levonorgestrel-ethinyl estradiol) TYBLUME (levonorgestrel-ethinyl estradiol) chewable VOLNEA (desogestrel-ethinyl estradiol/ethinyl estradiol) WYMZYA FE (norethindrone-ethinyl estradiol-FE) chewable	AVERI (desogestrel-ethinyl estradiol-FE) BALCOLTRA (levonorgestrel-ethinyl estradiol-FE) BEYAZ (drospironone-ethinyl estradiol-levomefolate) drospironone-ethinyl estradiol-levomefolate FEMLYV (norethindrone-ethinyl estradiol) GEMMILY (norethindrone-ethinyl estradiol-FE) GENERESS FE (norethindrone-ethinyl estradiol-FE) chewable KAITLIB FE (norethindrone-ethinyl estradiol) chewable LAYOLIS FE (norethindrone-ethinyl estradiol-FE) chewable levonorgestrel-ethinyl estradiol 90-20 levonorgestrel-ethinyl estradiol-FE (gen BALCOLTRA) LOESTRIN (norethindrone-ethinyl estradiol) LOESTRIN-FE (norethindrone-ethinyl estradiol-FE) MERZEE (norethindrone-ethinyl estradiol-FE) MINASTRIN (norethindrone-ethinyl estradiol) MINZOYA (levonorgestrel-ethinyl estradiol-FE) NEXTSTELLIS (drospironone-estetrol) SAFYRAL (drospironone-ethinyl estradiol-levomefolate) TAYSOFY (norethindrone-ethinyl estradiol-FE) TAYTULLA (norethindrone-ethinyl estradiol) YASMIN (drospironone-ethinyl estradiol) YAZ (drospironone-ethinyl estradiol)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
CONTRACEPTIVES, ORAL - EXTENDED CYCLE Review Schedule: 1st Quarter		
AMETHIA LO (levonorgestrel-ethinyl estradiol) CAMRESE (levonorgestrel-ethinyl estradiol) CAMRESE LO (levonorgestrel-ethinyl estradiol-ethinyl estradiol) JOLESSA (levonorgestrel-ethinyl estradiol) levonorgestrel-ethinyl estradiol 0.15-0.03, 0.1-0.02 levonorgestrel-ethinyl estradiol-ethinyl estradiol 150-30, 100-20	levonorgestrel-ethinyl estradiol-ethinyl estradiol 0.15	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
CONTRACEPTIVES, ORAL - PROGESTINS Review Schedule: 1st Quarter		
EMZAHH (norethindrone) LYLEQ (norethindrone) NORA-BE (norethindrone) norethindrone OPILL (norgestrel) SLYND (drospironone)		

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
CONTRACEPTIVES, ORAL – TRIPHASIC		Review Schedule: 1st Quarter
ALYACEN (norethindrone-ethinyl estradiol) ARANELLE (norethindrone-ethinyl estradiol) CAZIAN (desogestrel-ethinyl estradiol) DASETTA (norethindrone-ethinyl estradiol) ENPRESSE (levonorgestrel-ethinyl estradiol) FINZALA (norethindrone-ethinyl estradiol-iron) LEENA (norethindrone-ethinyl estradiol) LEVONEST (levonorgestrel-ethinyl estradiol) levonorgestrel-ethinyl estradiol NORTREL (norethindrone-ethinyl estradiol) NYLIA (norethindrone-ethinyl estradiol) norethindrone-ethinyl estradiol-iron norgestimate-ethinyl estradiol TILIA FE (norethindrone-ethinyl estradiol-iron) TRI-ESTARYLLA (norgestimate-ethinyl estradiol) TRI-LINYAH (norgestimate-ethinyl estradiol) TRI-MILLI (norgestimate-ethinyl estradiol) TRY-NYMYO (norgestimate-ethinyl estradiol) TRI-SPRINTEC (norgestimate-ethinyl estradiol) TRI-VYLIBRA (norgestimate-ethinyl estradiol) TRIVORA (levonorgestrel-ethinyl estradiol) VELIVET (desogestrel-ethinyl estradiol)	TRI-LEGEST (norethindrone-ethinyl estradiol-iron)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
CONTRACEPTIVES – IUDs / IMPLANTS		Review Schedule: 1st Quarter
KYLEENA (levonorgestrel) LILETTA (levonorgestrel) MIRENA (levonorgestrel) NEXPLANON (etonogestrel) PARAGARD		
CONTRACEPTIVES – PATCHES		Review Schedule: 1st Quarter
ethinyl estradiol-norelgestromin	TWIRLA (levonorgestrel-ethinyl estradiol) XULANE (ethinyl estradiol-norelgestromin) ZAFEMY (ethinyl estradiol-norelgestromin)	<ul style="list-style-type: none"> One (1) preferred product required before a non-preferred product will be approved.
CONTRACEPTIVES – VAGINAL RINGS		Review Schedule: 1st Quarter
ELURYNG (etonogestrel-ethinyl estradiol) ENILLORING (etonogestrel-ethinyl estradiol) etonogestrel-ethinyl estradiol HALOETTE (etonogestrel-ethinyl estradiol)	ANNOVERA (ethinyl estradiol-segesterone)	<ul style="list-style-type: none"> One (1) preferred product required before a non-preferred product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
GROWTH HORMONES (Clinical criteria applies to class. All agents require a prior authorization.) Review Schedule: 4th Quarter		
GENOTROPIN (somatropin) NGENLA (somatrogon-ghla) NORDITROPIN (somatropin) SOGROYA (somapacitan-beco)	NUTROPIN AQ (somatropin) OMNITROPE (somatropin) SAIZEN (somatropin) SEROSTIM (somatropin) SKYTROFA (lonapegsomatropin-tcgd) ZOMACTON (somatropin) ZORBTIVE (somatropin)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
HYPERPARATHYROIDS Review Schedule: 4th Quarter		
calcitriol capsule cinacalcet tablet	calcitriol solution doxercalciferol paricalcitol capsule SENISPAR (cinacalcet) RAYALDEE (calcifediol) ROCALTROL (calcitriol) ZEMPLAR (paricalcitol) capsule, vial	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
HYPOGLYCEMIA TREATMENTS Review Schedule: 4th Quarter		
BAQSIMI (glucagon) (Amphastar – labeler code 00548) glucagon PROGLYCEM (diazoxide) ZEGALOGUE autoinjector (dasiglucagon) (Novo Nordisk – labeler code 00169) ZEGALOGUE syringe (dasiglucagon) (Novo Nordisk – labeler code 00169)	BAQSIMI (glucagon) (Lilly – labeler code 00002) diazoxide GVOKE HYPOPEN (glucagon) GVOKE PFS (glucagon) GVOKE kit (glucagon)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
HYPOGLYCEMICS, ALPHA-GLUCOSIDASE INHIBITORS Review Schedule: 1st Quarter		
acarbose	GLYSET (migitol) miglitol	<ul style="list-style-type: none"> One (1) preferred product required before a non-preferred product will be approved.
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS: DPP-4 INHIBITORS (Clinical criteria applies to class. All agents require a prior authorization.) Review Schedule: 4th Quarter		
JANUMET (sitagliptin phos/metformin) JANUMET XR (sitagliptin phos/metformin) JANUVIA (sitagliptin phos) JENTADUETO (linagliptin/metformin) TRADJENTA (linagliptin)	alogliptin alogliptin/metformin alogliptin/pioglitazone BRYNOVIN (sitagliptin) JENTADUETO XR (linagliptin/metformin) KOMBIGLYZE XR (saxagliptin/metformin) linagliptin/metformin	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
	NESINA (alogliptin) OSENI (alogliptin/pioglitazone) saxagliptin saxagliptin/metformin sitagliptin (gen ZITUVIO) sitagliptin/metformin (gen ZITUVIMET) sitagliptin/metformin ER (gen ZITUVIMET XR) ZITUVIO (sitagliptin) ZITUVIMET (sitagliptin/metformin) ZITUVIMET XR (sitagliptin/metformin)	
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS: GLP-1 RAs (Clinical criteria applies to class. All agents require a prior authorization.)		Review Schedule: 4th Quarter
OZEMPIC (semaglutide) TRULICITY (dulaglutide)	exenatide liraglutide MOUNJARO (tirzepatide) RYBELSUS (semaglutide) SOLIQUA (insulin glargine/lixisenatide) VICTOZA (liraglutide) XULTOPHY (insulin degludec/liraglutide)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
HYPOGLYCEMICS, INSULINS		Review Schedule: 4th Quarter
HUMALOG MIX 50-50 (insulin lispro/lispro protamine) HUMALOG MIX 75-25 (insulin lispro/lispro protamine) vial HUMULIN R U-500 (insulin) HUMULIN R vial HUMULIN 70-30 vial insulin lispro insulin lispro mix LANTUS (insulin glargine) LANTUS SOLOSTAR (insulin glargine) NOVOLIN N (insulin isophane) NOVOLIN R (insulin) NOVOLOG (insulin aspart) NOVOLOG MIX 70/30 TOUJEO SOLOSTAR (insulin glargine) TOUJEO SOLOSTAR MAX (insulin glargine)	ADMELOG (insulin lispro) AFREZZA (insulin) APIDRA (insulin glulisine) BASAGLAR (insulin glargine) BASAGLAR TEMPO (insulin glargine) FIASP (insulin aspart) HUMALOG U-100 (insulin lispro) HUMALOG U-200 (insulin lispro) HUMALOG JUNIOR (insulin lispro) HUMALOG MIX 75-25 (insulin lispro/lispro protamine) pen HUMULIN N HUMULIN 70/30 pen insulin aspart insulin aspart mix insulin degludec insulin glargine SOLOSTAR (gen TOUJEO) Insulin glargine SOLOSTAR MAX (gen TOUJEO) insulin glargine-YFGN insulin glargine KIRSTY (insulin aspart-xjhz) LYUMJEV (insulin lispro) MERILOG (insulin aspart-szjj) MERILOG SOLOSTAR (insulin aspart-szjj)	

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
	NOVOLIN N (insulin isophane) vial NOVOLIN R (insulin) vial NOVOLIN 70/30 RELION NOVOLIN N, NOVOLIN R, NOVOLOG REZVOGLAR KWIKPEN (insulin glargine-aglr) SEMGLEE (insulin glargine) TRESIBA (insulin degludec)	
HYPOGLYCEMICS, MEGLITINIDES		Review Schedule: 1st Quarter
nateglinide repaglinide		
HYPOGLYCEMICS, METFORMINS		Review Schedule: 4th Quarter
glipizide-metformin glyburide-metformin metformin IR 500 mg, 850 mg, 1000 mg metformin ER (generic GLUCOPHAGE XR)	metformin ER (generic FORTAMET, GLUMETZA) metformin IR solution metformin IR 625 mg, 750 mg * RIOMET (metformin IR)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. * PA required, to include reason preferred metformin product, cannot be used, before product will be approved.
HYPOGLYCEMICS, SGLT2 INHIBITORS		Review Schedule: 4th Quarter
FARXIGA (dapagliflozin) INVOKAMET (canagliflozin/metformin) INVOKAMET XR (canagliflozin/metformin) INVOKANA (canagliflozin) JARDIANCE (empagliflozin) SYNJARDY (empagliflozin/metformin) XIGDUO XR (dapagliflozin/metformin)	dapagliflozin dapagliflozin/metformin GLYXAMBI (empagliflozin/linagliptin) SEGLUROMET (ertugliflozin/metformin) STEGLATRO (ertugliflozin) STEGLUJAN (ertugliflozin/sitagliptin) SYNJARDY XR (empagliflozin/metformin) TRIJARDY XR (empagliflozin/linagliptin/metformin)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
HYPOGLYCEMICS, TZDs		Review Schedule: 1st Quarter
pioglitazone	ACTOPLUS MET (pioglitazone/metformin) ACTOS (pioglitazone) DUETACT (pioglitazone/glimepiride) pioglitazone/glimepiride pioglitazone/metformin	<ul style="list-style-type: none"> One (1) preferred product required before a non-preferred product will be approved.
GLUCOCORTICOIDS, ORAL		Review Schedule: 4th Quarter
budesonide ER capsule dexamethasone elixir, intensol, solution, tablet fludrocortisone hydrocortisone	AGAMREE (vamorolone) * ALKINDI SPRINKLES (hydrocortisone) granules budesonide ER tablet CORTEF (hydrocortisone)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
methylprednisolone dose pack methylprednisolone 4mg tablet prednisolone solution prednisolone sodium phosphate solution prednisone dose pack, IR tablet	cortisone deflazacort dexamethasone dose pack EMFLAZA (deflazacort) EOHILIA (budesonide) HEMADY (dexamethasone) JAYTHARI (deflazacort) KHINDIVI (hydrocortisone) MEDROL (methylprednisolone) methylprednisolone 8, 16, 32 mg tablet prednisolone tablet prednisolone sodium phosphate ODT prednisone intensol, solution, DR tablet PYQUVI (deflazacort) TARPEYO (budesonide)	<ul style="list-style-type: none"> * Step through 3-month trial of prednisone and 3-month trial of Emflaza required before product will be approved.
NON-ALCOHOLIC STEATOHEPATITIS (NASH) TREATMENT AGENTS (Clinical criteria applies to class.)		Review Schedule: 2nd Quarter
	REZDIFFRA (resmetriom)	
PELVIC DISORDERS – ENDOMETRIOSIS, UTERINE FIBROIDS		Review Schedule: 4th Quarter
danazol DEPO-SUBQ PROVERA 104 (medroxyprogesterone) LUPRON DEPOT (leuprolide) MYFEMBREE (relugolix-estradiol-norethindrone acetate) norethindrone acetate ORLISSA (elagolix) SYNAREL (nafarelin)	ORIAHNN (elagolix-estradiol-norethindrone)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
PITUITARY SUPPRESSANTS, CENTRAL PRECOCIOUS PUBERTY (CPP) (Clinical criteria applies to class.)		Review Schedule: 4th Quarter
FENSOLVI (leuprolide acetate) leuprolide acetate 22.5 mg vial LUPRON DEPOT–PED 1-month (leuprolide) SYNAREL (nafarelin)	LUPRON DEPOT–PED 3-month, 6-month (leuprolide) SUPPRELIN LA (histrelin) TRIPTODUR (triptorelin)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
POTASSIUM REMOVING AGENTS		Review Schedule: 4th Quarter
LOKELMA (sodium zirconium cyclosilicate) sodium polystyrene sulfonate VELTASSA (patiromer calcium sorbitex)		

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
PROGESTATIONAL AGENTS Review Schedule: 2nd Quarter		
medroxyprogesterone acetate tablet medroxyprogesterone acetate IM norethindrone acetate tablet progesterone capsule progesterone IM	CRINONE (progesterone) DEPO-PROVERA (medroxyprogesterone) progesterone insert PROMETRIUM (progesterone) PROVERA (medroxyprogesterone)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
THYROID HORMONES Review Schedule: 4th Quarter		
ARMOUR THYROID (thyroid desiccated) ERMEZA (levothyroxine sodium) LEVO-T (levothyroxine sodium) levothyroxine sodium tablet liothyronine sodium tablet LIOMNY (liothyronine sodium) NP THYROID (thyroid desiccated)	ADTHYZA (thyroid desiccated) CYTOMEL (liothyronine sodium) EVEXITHROID (thyroid desiccated) levothyroxine sodium injection LEVOXYL (levothyroxine sodium) liothyronine sodium injection RENTHYROID (thyroid desiccated) SYNTHROID (levothyroxine sodium) THYQUIDITY (levothyroxine sodium) UNITHROID (levothyroxine sodium)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
UREA CYCLE DISORDER AGENTS Review Schedule: 4th Quarter		
carglumic acid (Eton – labeler code 71863) PHEBURANE (sodium phenylbutyrate) RAVICTI (glycerol phenylbutyrate) sodium phenylbutyrate powder, tabs	BUPHENYL powder, tabs (sodium phenylbutyrate) CARBAGLU (carglumic acid) carglumic acid (Burel – labeler code 35573) glycerol phenylbutyrate LOARGYS (pegzilarginase-nbln) OLPRUVA (sodium phenylbutyrate)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
VASOMOTOR SYMPTOMS Review Schedule: 4th Quarter		
	LYNKUET (elinzanetant) VEOZAH (fezolinetant)	
GASTROINTESTINAL AGENTS		
ANTIEMETICS, ORAL/TRANSDERMAL Review Schedule: 4th Quarter (Clinical criteria applies to individual agents in class.)		
DICLEGIS (doxylamine/pyridoxine) ondansetron tablet, ODT (4mg, 8 mg), solution scopolamine patch	AKYNZEO (netupitant/palonosetron) aprepitant BONJESTA (doxylamine/pyridoxine) * doxylamine/pyridoxine	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
	dronabinol * EMEND (aprepitant) capsule, suspension granisetron MARINOL (dronabinol) * ondansetron ODT 16 mg SANCUSO (granisetron) TRANSDERM-SCOP (scopolamine) trimethobenzamide	<ul style="list-style-type: none"> * Clinical criteria applies
BILE SALTS		Review Schedule: 4th Quarter
ursodiol capsule, tablet	CHENODAL (chenodiol) CHOLBAM (cholic acid) IQIRVO (elafibranor) LIVDELZI (seladelpar) RELTONE (ursodiol) URSO FORTE (ursodiol)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
BOWEL PREP		Review Schedule: 4th Quarter
CLENPIQ GAVILYTE-C GAVILYTE-G GOLYTELY NULYTELY PEG 3350 PEG 3350-ELECTROLYTE PEG 3350-Sod Sul-NACL-KCL- ASB-C SODIUM SULF-POTASSIUM SULF-MAG SULF SUPREP	SUFLAVE SUTAB	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
CONSTIPATION – IBS, ORAL		Review Schedule: 4th Quarter
LINZESS (linaclotide) lubiprostone MOVANTIK (naloxegol)	AMITIZA (lubiprostone) ISBRELA (tenapanor) MOTEGRITY (prucalopride) prucalopride SYMPROIC (naldemedine)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
DIARRHEA – IBS, ORAL		Review Schedule: 4th Quarter
	alosetron LOTRONEX (alosetron) MYTESI (crofelemer) VIBERZI (eluxadoline)	
H. PYLORI TREATMENTS		Review Schedule: 4th Quarter
	bismuth-metronidazole- tetracycline	

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
PYLERA (bismuth subcitrate potassium-metronidazole-tetracycline)	lansoprazole-amoxicillin-clarithromycin OMECLAMOX PAK (omeprazole-clarithromycin-amoxicillin) TALICIA (omeprazole magnesium-amoxicillin-rifabutin) VOQUEZNA DUAL PAK (vonoprazan-amoxicillin) VOQUEZNA TRIPLE PAK (vonoprazan-amoxicillin-clarithromycin)	<ul style="list-style-type: none"> One (1) preferred product required before a non-preferred product will be approved.
HISTAMINE II RECEPTOR BLOCKERS		Review Schedule: 1st Quarter
famotidine nizatidine	cimetidine ranitidine	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
HYPERPHOSPHATEMIA AGENTS, OTHER		Review Schedule: 1st Quarter
	XPHOZAH (tenapanor)	<ul style="list-style-type: none"> Two (2) preferred phosphate binder products required before a non-preferred product will be approved. PA required for all non-calcium-based products.
HYPERPHOSPHATEMIA AGENTS, PHOSPHATE BINDERS		Review Schedule: 1st Quarter
calcium acetate capsule sevelamer carbonate tablet	AURYXIA (ferric citrate) calcium acetate tablet ferric citrate FOSRENOL (lanthanum carbonate) lanthanum RENAGEL (sevelamer HCl) REVELA (sevelamer carbonate) sevelamer HCl tablet sevelamer powder VELPHORO (sucroferric oxyhydroxide)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. PA required for all non-calcium based products.
PANCREATIC ENZYMES		Review Schedule: 4th Quarter
CREON (pancrelipase) ZENPEP (pancrelipase)	PERTZYE (pancrelipase) VIOKACE (pancrelipase)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
PROTON PUMP INHIBITORS		Review Schedule: 1st Quarter
esomeprazole packet * omeprazole RX pantoprazole tablet PROTONIX (pantoprazole) granules	DEXILANT (dexlansoprazole) dexlansoprazole esomeprazole capsule, tablet KONVOMEK (omeprazole/sodium bicarbonate) lansoprazole NEXIUM (esomeprazole) omeprazole OTC	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. Quantity limits apply to class. * Requires prior authorization for members ≥ 10-years old

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
	omeprazole/sodium bicarbonate pantoprazole granules PREVACID (lansoprazole) PRILOSEC (omeprazole) packet PROTONIX (pantoprazole) tablet rabeprazole VOQUENZA (vonoprazan)	
ULCERATIVE COLITIS AGENTS		Review Schedule: 3rd Quarter
balsalazide mesalamine enema, suppository mesalamine DR 1.2 gm tablet mesalamine ER 375 mg capsule PENTASA (mesalamine) sulfasalazine sulfasalazine DR	AZULFIDINE (sulfasalazine) budesonide foam CANASA (mesalamine) DIPENTUM (olsalazine) LIALDA (mesalamine) mesalamine DR 400 mg capsule mesalamine DR 800 mg tablet mesalamine enema kit mesalamine ER 500 mg capsule ROWSA (mesalamine) SFROWSA (mesalamine)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
GENE THERAPY		
CENTRAL NERVOUS SYSTEM, SPINAL MUSCULAR ATROPHY (Clinical criteria applies to class. All agents require a prior authorization.)		
ZOLGENSMA (onasemnogene abeparvec)		
HEMATOLOGICAL, SICKLE CELL DISEASE (Clinical criteria applies to class. All agents require a prior authorization.)		
CASGEVY (exagamglogene autotemcel) LYFGENIA (lovotibeglogene autotemcel)		
TOPICAL, RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (Clinical criteria applies to class. All agents require a prior authorization.)		
ZEVASKYN (prademagene zamikeracel)		
GENITOURINARY PRODUCTS		
BLADDER RELAXANT PREPARATIONS		Review Schedule: 4th Quarter
MYRBETRIQ (mirabegron) tablet	darifenacin	

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
oxybutynin 5 mg oxybutynin ER oxybutynin syrup solifenacin	fesoterodine GEMTESA (vibegron) mirabegron tablet MYRBETRIQ (mirabegron) suspension oxybutynin 2.5 mg OXYTROL (oxybutynin) tolterodine TOVIAZ (fesoterodine) trospium VESICARE (solifenacin) tablet VESICARE LS (solifenacin) suspension	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
BPH TREATMENTS		Review Schedule: 2nd Quarter
alfuzosin doxazosin finasteride 5 mg tamsulosin terazosin	CARDURA (doxazosin) CARDURA XL (doxazosin) dutasteride dutasteride/tamsulosin PROSCAR (finasteride) RAPAFLO (silodosin) silodosin tadalafil 5 mg *	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. * For BPH diagnosis only
HEMATOLOGICAL AGENTS		
ANTICOAGULANTS, ORAL/SQ		Review Schedule: 4th Quarter
dabigatran ELIQUIS (apixaban) tablet enoxaparin JANTOVEN (warfarin) warfarin rivaroxaban tablet XARELTO (rivaroxaban) tablet (except 2.5 mg)	ARIXTRA (fondaparinux) ELIQUIS (apixaban) sprinkle, tablet for suspension fondaparinux FRAGMIN (dalteparin) LOVENOX (enoxaparin) PRADAXA (dabigatran) rivaroxaban suspension SAVAYSA (edoxaban) XARELTO (rivaroxaban) 2.5 mg tablet, suspension	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. Quantity limits in place on injectable formulations: 6 weeks allowed without prior authorization.
HEMOPHILIA A/VWD		Review Schedule: 4th Quarter
AFSTYLA (antihemophilic factor – recombinant) ALPHANATE (antihemophilic factor/von Willebrand factor complex- human) FEIBA (anti-inhibitor coagulant complex) HEMLIBRA (emicizumab-kxwh) HEMOFIL M (antihemophilic factor – human) HUMATE-P (antihemophilic factor/von Willebrand factor complex- human) JIVI (antihemophilic factor – recombinant) KOATE (antihemophilic factor – recombinant)	ADVATE (antihemophilic factor – recombinant) ADYNOVATE (antihemophilic factor – recombinant) ALHEMO (concizumab-mtci) * ALTUVIII0 (antihemophilic factor – recombinant) ELOCTATE (antihemophilic factor – recombinant) ESPEROCT (antihemophilic factor – recombinant) HYMPAVZI (marstacimab-hncq) * KOGENATE FS (antihemophilic factor – recombinant) QFITLIA (fitusiran) *	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. * Approval criteria dependent on diagnosis (Dx) <ul style="list-style-type: none"> Dx hemophilia B – use of preferred product not required prior to approval. Dx hemophilia A – use of or contraindication to Hemlibra required before non-preferred product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
KOVALTRY (antihemophilic factor – recombinant) NOVOSEVEN (coagulation factor VIIa – recombinant) NOVOEIGHT (antihemophilic factor – recombinant) NUWIQ (antihemophilic factor – recombinant) OBIZUR (antihemophilic factor – recombinant) WILATE (von Willebrand factor/coagulation factor VIII complex – human) XYNTHA (antihemophilic factor – recombinant) XYNTHA SOLOFUSE (antihemophilic factor – recombinant)	RECOMBINATE (antihemophilic factor – recombinant) SEVENFACT (coagulation factor VIIa – recombinant) VONVENDI (von Willebrand factor – recombinant)	
HEMOPHILIA B		Review Schedule: 4th Quarter
ALPHANINE SD (coagulation factor IX – human) ALPROLIX (coagulation factor IX – recombinant) BENEFIX (coagulation factor IX – recombinant) IXINITY (coagulation factor IX – recombinant) REBINYN (coagulation factor IX – recombinant) PROFILNINE (factor IX complex) RIXUBIS (coagulation factor IX – recombinant)	IDELVION (coagulation factor IX – recombinant)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
COLONY STIMULATING FACTORS		Review Schedule: 4th Quarter
FULPHILA (pegfilgrastim-jmdb) NEUPOGEN (filgrastim) NYVEPRIA (pegfilgrastim-apgf)	FYLNETRA (pegfilgrastim-pbbk) GRANIX (tbo-filgrastim) LEUKINE (sargramostim) NEULASTA (pegfilgrastim) NIVESTYM (figrastim-aafi) vial, syringe NYPOZI (filgrastim-txid) RELEUKO (filgrastim-ayow) ROLVEDON (eflapegrastim-xnst) RYZNEUTA (efbemalenograstim alfa-vuxw) STIMUFEND (pegfilgrastim-fpgk) UDENYCA (pegfilgrastim-cbqv) ZARXIO (filgrastim-sndz) ZIEXTENZO (pegfilgrastim-bmez)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
ERYTHROPOIESIS STIMULATING PROTEINS (Clinical criteria applies to class. All agents require a prior authorization.)		Review Schedule: 4th Quarter
MIRCERA (methoxy polyethylene glycol-epoetin beta) RETACRIT (epoetin alfa-epbx) (Pfizer – labeler code 00069)	ARANESP (darbepoetin alfa) EPOGEN (epoetin alfa) PROCRIT (epoetin alfa) RETACRIT (epoetin alfa-epbx) (Vifor – labeler code 59353)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
HAE TREATMENTS (Clinical criteria applies to class. All agents require a prior authorization.) Review Schedule: 4th Quarter		
BERINERT (human C1 inhibitor) CINRYZE (human C1 inhibitor) danazol HAEGARDA (human C1 inhibitor) icatibant KALBITOR (escalantide) ORLADEYO (berotralstat) capsule RUCONEST (recombinant C1 esterase inhibitor) TAKHZYRO (lanadelumab-flyo)	ANDEMBRY (garadaciman-gxii) DAWNZERA (donidalorsen) FIRAZYR (icatibant) ORLADEYO (berotralstat) pellets SAJAZIR (icatibant)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
PLATELET AGGREGATION INHIBITORS Review Schedule: 4th Quarter		
aspirin/dipyridamole clopidogrel dipyridamole prasugrel ticagrelor	aspirin/omeprazole BRILINTA (ticagrelor) EFFIENT (prasugrel) PLAVIX (clopidogrel) ticlopidine YOSPRALA (aspirin/omeprazole) ZONTIVITY (vorapaxar)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
SICKLE CELL ANEMIA AGENTS Review Schedule: 4th Quarter		
DROXIA (hydroxyurea) hydroxyurea XROMI (hydroxyurea) *	ADAKVEO (crizanlizumab-tmca) vial ENDARI (glutamine) HYDREA (hydroxyurea) SIKLOS (hydroxyurea)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. * Requires prior authorization for members ≥ 10-years old
THROMBOPOIETICS Review Schedule: 2nd Quarter		
NPLATE (romiplostim) PROMACTA (eltrombopag olamine) tablet	ALVAIZ (eltrombopag choline) DOPTELET (avatrombopag maleate) eltrombopag olamine MULPLETA (lusutrombopag) PROMACTA (eltrombopag olamine) powder pack TAVALISSE (fostanatiniv disodium) WAYRILZ (rilzabrutinib)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
IMMUNE GLOBULINS		
IMMUNE GLOBULINS		Review Schedule: 4th Quarter
BIVIGAM GAMMAGARD GAMMAGARD S-D GAMMAGARD ERC GAMUNEX-C OCTAGAM PRIVIGEN XEMBIFY	ALYGLO ASCENIV CUTAQUIG CUVITRU GAMASTAN GAMMAKED GAMMAPLEX HIZENTRA HYQVIA PANZYGA QIVIGY	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
MEDICAL DEVICES AND SUPPLIES		
BLOOD GLUCOSE METERS, TEST STRIPS		
Please refer to the Delaware Pharmacy Corner website for covered Diabetic Supply products. https://medicaid.dhss.delaware.gov/provider/Home/PharmacyCornerLanding/tabid/2096/Default.aspx	All other blood glucose meters and test strips are non-preferred	Two (2) preferred products required before a non-preferred product will be approved.
CONTINUOUS GLUCOSE MONITORS (CGMs)		
Please refer to the Delaware Pharmacy Corner website for covered Diabetic Supply products. https://medicaid.dhss.delaware.gov/provider/Home/PharmacyCornerLanding/tabid/2096/Default.aspx	All other CGM devices are non-preferred	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
INSULIN PUMPS (Clinical criteria applies to class. All preferred agents require prior authorization. All non-preferred insulin pumps are not covered under pharmacy)		
Please refer to the Delaware Pharmacy Corner website for covered Diabetic Supply products. https://medicaid.dhss.delaware.gov/provider/Home/PharmacyCornerLanding/tabid/2096/Default.aspx	All other insulin pumps are non-preferred.	<ul style="list-style-type: none"> All other insulin pumps are not payable under the pharmacy benefit. These claims need to be billed under the Durable Medical Equipment benefit.
RESPIRATORY DEVICES		
ACE AEROSOL CLOUD ENHANCER SPACER EASIVENT EASIVENT SPACER	AEROCHAMBER PLUS FLOW-VU FLEXICHAMBER MASK FLEXICHAMBER SPACER	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
	SPRITAM (levetiracetam) SYMPAZAN (clobazam) TEGRETOL (carbamazepine) suspension, tablet TEGRETOL XR (carbamazepine) tiagabine tablet TOPAMAX (topiramate) topiramate ER topiramate solution topiramate sprinkle capsule * TRILEPTAL (oxcarbazepine) suspension, tablet TROKENDI XR (topiramate) vigabatrin VIGADRONE (vigabatrin) VIGAFYDE (vigabatrin) ** VIMPAT (lacosamide) XCOPRI (cenobamate) ZARONTIN (ethosuximide) ZONISADE (zonisamide) ZTALMY (ganaxolone)	
ANTIPARKINSON'S AGENTS, ORAL/TRANSDERMAL		Review Schedule: 1st Quarter
amantadine capsule, solution benztropine bromocriptine carbidopa/levodopa IR, ER tablet entacapone pramipexole IR ropinirole IR selegiline capsule, tablet trihexyphenidyl	amantadine tablet AZILECT (rasagiline) carbidopa carbidopa/levodopa ER capsule, ODT carbidopa/levodopa/entacapone COMTAN (entacapone) CREXONT ER (carbidopa/levodopa) DHIVY (carbidopa/levodopa) DUOPA (carbidopa/levodopa) GOCOVRI (amantadine) INBRIJA (levodopa) NEUPRO (rotigotine) NOURIANZ (istradefylline) ONAPGO (apomorphine) ONGENTYS (opicapone) pramipexole ER rasagiline ropinirole ER RYTARY (carbidopa/levodopa) SINEMET 10-100 (carbidopa/levodopa) STALEVO (carbidopa/levodopa/entacapone) VYALEV (foscarbidopa/foslevodopa) XADAGO (safinamide)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
SKELETAL MUSCLE RELAXANTS (Clinical criteria applies to individual agents in class.)		Review Schedule: 3rd Quarter
baclofen 5 mg, 10 mg, 20 mg tablet cyclobenzaprine 5 mg, 10 mg tablet methocarbamol 500 mg, 750 mg tablet	AMRIX (cyclobenzaprine) baclofen 15 mg tablet, solution **, suspension carisoprodol ***	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
tizanidine tablet	carisoprodol compound with codeine * chlorzoxazone cyclobenzaprine 7.5 mg tablet cyclobenzaprine ER DANTRIUM (dantrolene) dantrolene FEXMID (cyclobenzaprine) FLEQSUVY (baclofen) LYVISPAH (baclofen) metaxalone ^ methocarbamol 1000 mg tablet ONTRALFY (tizanidine) ^ orphenadrine orphenadrine, aspirin, caffeine OZOBAX (baclofen) OZOBAX DS (baclofen) SOMA (carisoprodol) *** TANLOR (methocarbamol) tizanidine capsule ^ TONMYA (cyclobenzaprine) ^^ ZANAFLEX (tizanidine) capsule ^, tablet	<ul style="list-style-type: none"> Total quantity limit of 120 units of muscle relaxants, with the exception of baclofen products, per 30 rolling days. * Clinical PA required ** PA required, to include reason baclofen suspension cannot be used, before product will be approved. ***Carisoprodol quantity limit – 84 units per 90 days ^ PA required for 640 mg, to include reason 400 mg or 800 mg tablets cannot be used, before product will be approved. ^ PA required, to include reason tizanidine tablet cannot be used, before product will be approved. ^^ PA required, to include reason cyclobenzaprine tablet cannot be used, before product will be approved.
NUTRITIONAL PRODUCTS		
PRENATAL VITAMINS		Review Schedule: 1st Quarter
COMPLETE NATAL DHA M-NATAL PLUS NIVA-PLUS PNV 29-1 PRENATAL PLUS PRENATAL VITAMIN plus LOW IRON PREPLUS PRETAB THRIVITE RX TRINATAL RX 1 TRIVEEN-DUO DHA VOL-PLUS VP-PNV-DHA WESNATAL DHA COMPLETE WESTAB PLUS	All other prenatal products non-preferred	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
OBESITY TREATMENT AGENTS (Clinical criteria applies to class. All agents require a prior authorization.)		Review Schedule: 4th Quarter
CONTRAVE ER (naltrexone/bupropion ER) phentermine capsule, 37.5 mg tablet WEGOVY (semaglutide) pen-injector ZEPBOUND (tirzepatide) auto-injector	ADIPEX-P (phentermine) benzphetamine HCl diethylpropion HCl diethylpropion HCl ER liraglutide pen injector	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
	LOMAIRA (phentermine) orlistat phendimetrazine tartrate phendimetrazine tartrate ER phentermine 8 mg tablet phentermine/topiramate ER SAXENDA (liraglutide) pen injector WEGOVY (semaglutide) tablet XENICAL (orlistat) ZEPBOUND KWIKPEN (tirzepatide) pen-injector	
OVER THE COUNTER DRUGS		
Review Schedule: 3rd Quarter		
Please refer to the Delaware Pharmacy Corner website for covered OTC products. https://medicaid.dhss.delaware.gov/provider/Home/PharmacyCornerLanding/tabid/2096/Default.aspx		
PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS		
ALZHEIMER'S AGENTS		
Review Schedule: 3rd Quarter		
donepezil 5 mg, 10 mg tablet memantine tablet rivastigmine patch	ARICEPT (donepezil) donepezil ODT donepezil 23 mg tablet EXELON (rivastigmine) patch galantamine LEQEMBI (lecanemab-irmb) memantine capsule, solution memantine/donepezil ER NAMENDA XR (memantine) NAMZARIC (memantine/donepezil) RAZADYNE ER (galantamine) rivastigmine capsule ZUNVEYL DR (benzgalantamine)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
MOVEMENT DISORDER		
Review Schedule: 4th Quarter		
AUSTEDO (deutetrabenazine) INGREZZA (valbenazine) * tetrabenazine	AUSTEDO XR (deutetrabenazine) INGREZZA SPRINKLE (valbenazine) XENAZINE (tetrabenazine)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. * Ingrezza quantity limit – 1 capsule per day
MULTIPLE SCLEROSIS (Clinical criteria applies to individual agents in class.)		
Review Schedule: 4th Quarter		
AVONEX (interferon beta-1a) * BRIUMVI (ublituximab-xiyy)	AMPYRA (dalfampridine) AUBAGIO (teriflunomide)	

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
dalfampridine dimethyl fumarate fingolimod glatiramer GLATOPA (glatiramer acetate) KESIMPTA (ofatumumab) REBIF (interferon beta-1a) * REBIF REBIDOSE (interferon beta-1a) * teriflunomide TYSABRI (natalizumab) *	BAFIERTAM (monomethyl fumarate) BETASERON (interferon beta-1b) * cladribine COPAXONE (glatiramer acetate) EXTAVIA (interferon beta-1b) GILENYA (fingolimod) LEMTRADA (alemtuzumab) MAVENCLAD (cladribine) MAYZENT (siponimod) OCREVUS (ocrelizumab) OCREVUS ZUNOVO (ocrelizumab) PLEGRIDY (peginterferon beta-1a) PONVORY (ponesimod) TASCENSO ODT (fingolimod) TECFIDERA (dimethyl fumarate) TYRUKO (natalizumab-sztn) * VUMERITY (diroximel fumarate) ZEPOSIA (ozanimod)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. * Clinical criteria applies
NEUROPATHIC PAIN		Review Schedule: 1st Quarter
gabapentin IR lidocaine patch 4%, 5% lidocaine/prilocaine cream pregabalin	gabapentin ER GRALISE (gabapentin) HORIZANT (gabapentin enacarbil) LYRICA CR (pregabalin) milnacipran NEURONTIN (gabapentin) pregabalin ER QUTENZA KIT (capsaicin/skin cleanser) SAVELLA (milnacipran HCl) ZTLIDO (lidocaine)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
RESPIRATORY AGENTS		
ANTIHISTAMINES, MINIMALLY SEDATING		Review Schedule: 3rd Quarter
cetirizine solution RX/OTC, tablet loratadine solution, tablet fexofenadine tablet	cetirizine capsule, chewable tablet cetirizine-D CLARINEX (desloratadine) CLARINEX-D (desloratadine/pseudoephedrine) desloratadine fexofenadine ODT, solution fexofenadine-D levocetirizine RX/OTC loratadine chewable tablet, ODT loratadine-D	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
BRONCHODILATORS, BETA AGONIST Review Schedule: 4th Quarter		
albuterol HFA (gen ProAir HFA, PROVENTIL HFA) albuterol nebulizer solution, syrup SEREVENT (salmeterol) STRIVERDI RESPIMAT (olodaterol) terbutaline VENTOLIN HFA (albuterol sulfate)	albuterol HFA (gen VENTOLIN HFA) albuterol tablet arformoterol vial BROVANA (arformoterol tartrate) formoterol vial levalbuterol HFA, vial PERFOROMIST (formoterol fumarate) PROAIR RESPICLICK (albuterol sulfate) XOPENEX HFA (levalbuterol)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
COPD AGENTS, SINGLE & DUAL AGENT COMBINATIONS Review Schedule: 4th Quarter		
albuterol/ipratropium nebulizer solution ANORO ELLIPTA (umeclidinium/vilanterol) ATROVENT HFA (ipratropium bromide) COMBIVENT (ipratropium bromide/albuterol) INCRUSE ELLIPTA (umeclidinium) ipratropium nebulizer solution SPIRIVA HANDIHALER (tiotropium bromide) SPIRIVA RESPIMAT (tiotropium bromide) STIOLTO RESPIMAT (tiotropium bromide/olodaterol)	BEVESPI (glycopyrrolate/formoterol fumarate) DALIRESP (roflumilast) DUAKLIR (acclidinium/formoterol) ipratropium bromide inhaler OHTUVAYRE (ensifentrine) * roflumilast tablet tiotropium bromide HFA TUDORZA (acclidinium bromide) umeclidinium/vilanterol YUPELRI (revefenacin)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. * Step through 3-month trial LABA + LAMA dual therapy, with or without ICS, required. <p>Abbreviations: LABA – long-acting beta₂ agonist LAMA – long-acting muscarinic antagonist ICS – inhaled corticosteroid</p>
COPD AGENTS, TRIPLE AGENT COMBINATIONS Review Schedule: 4th Quarter		
TRELEGY (fluticasone furoate, umeclidinium, vilanterol) *	BREZTRI (budesonide, glycopyrrolate, formoterol fumarate)	<ul style="list-style-type: none"> One (1) preferred products required before a non-preferred product will be approved. * Step through 3-month trial LABA + LAMA dual therapy, with or without ICS, required. <p>Abbreviations: LABA – long-acting beta₂ agonist LAMA – long-acting muscarinic antagonist ICS – inhaled corticosteroid</p>
COUGH AND COLD Review Schedule: 3rd Quarter		
benzonatate BROMFED DM (brompheniramine/dextromethorphan/pseudoephedrine) syrup brompheniramine/pseudoephedrine/DM syrup chlorpheniramine syrup, IR tablet dextromethorphan 15 mg capsule diphenhydramine capsule, liquid, tablet	All other cough and cold products are non-preferred	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. Quantity limits in place: <ul style="list-style-type: none"> Narcotic antitussives – 240 mL per 30 days and 480mL per 90 days without a comorbid diagnosis

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
guaifenesin liquid guaifenesin DM liquid, 400-20 mg tablet guaifenesin ER 600mg tablet guaifenesin/codeine syrup hydrocodone/homatropine syrup promethazine DM syrup promethazine/codeine syrup phenylephrine tablet pseudoephedrine liquid, IR tablet		<ul style="list-style-type: none"> ○ Tussionex – 120 mL per 84 days and 480 mL per year
GLUCOCORTICIDS, INHALED		Review Schedule: 4th Quarter
ADVAIR DISKUS, HFA (fluticasone propionate/salmeterol) ARNUITY ELLIPTA (fluticasone furoate) ASMANEX HFA (mometasone furoate) ASMANEX TWISTHALER (mometasone furoate) budesonide inhalation solution 0.25 mg, 0.5 mg * DULERA (mometasone furoate/formoterol fumarate) fluticasone propionate HFA * PULMICORT FLEXHALER (budesonide) (H2 Pharma – labeler 61269) QVAR REDHALER (beclomethasone dipropionate) SYMBICORT (budesonide/formoterol fumarate dihydrate)	AIRDUO RESPICLICK (fluticasone propionate/salmeterol) AIRSUPRA (albuterol sulfate/budesonide) ALVESCO (ciclesonide) beclomethasone HFA BREO ELLIPTA (fluticasone furoate/vilanterol) BREYNA (budesonide/formoterol fumarate) budesonide inhalation solution 1 mg budesonide/formoterol fumarate dihydrate fluticasone furoate Ellipta fluticasone/salmeterol diskus, HFA fluticasone/vilanterol PULMICORT (budesonide) inhalation solution WIXELA INHUB (fluticasone propionate/salmeterol)	<ul style="list-style-type: none"> • Two (2) preferred products required before a non-preferred product will be approved. • * Approval for budesonide may be generated by system for patients: <ul style="list-style-type: none"> ○ Aged 6 years and older AND with ○ Diagnosis on file indicating developmental delay • * Prior authorization required for ≥ 18 years of age.
INTRANASAL RHINITIS AGENTS		Review Schedule: 1st Quarter
azelastine 0.1% fluticasone RX ipratropium	azelastine 0.15% azelastine/fluticasone BECONASE AQ (beclomethasone dipropionate) budesonide OTC DYMISTA (azelastine/fluticasone) FLONASE SENSIMIST OTC (fluticasone) flunisolide fluticasone OTC mometasone NASACORT OTC (triamcinolone) NASONEX OTC (mometasone) olopatadine OMNARIS (ciclesonide) QNASL (beclomethasone dipropionate) RYALTRIS (olopatadine HCl/mometasone) SINUVA (mometasone) triamcinolone XHANCE (fluticasone propionate)	<ul style="list-style-type: none"> • Two (2) preferred products required before a non-preferred product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
LEUKOTRIENE RECEPTOR ANTAGONISTS Review Schedule: 4th Quarter		
montelukast tablet, chewable tablet	ACCOLATE (zafirlukast) montelukast granules SINGULAIR (montelukast) zafirlukast zileuton ER ZYFLO (zileuton)	<ul style="list-style-type: none"> One (1) preferred product required before a non-preferred will be approved.
MABs-ANTI-IL, ANTI-IGE (Clinical criteria applies to class. All agents require a prior authorization.) Review Schedule: 4th Quarter		
DUPIXENT (dupilumab) FASENRA (benralizumab) NUCALA (mepolizumab) TEZSPIRE (tezepelumab-ekko) XOLAIR (omalizumab)	CINQAIR (reslizumab) EXDENSUR (depemokimab-ulaa) RHAPSIDO (remibrutinib)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
STIMULANTS AND RELATED AGENTS		
NARCOLEPTIC AGENTS Review Schedule: 4th Quarter		
armodafinil modafinil	NUVIGIL (armodafinil) PROVIGIL (modafinil) sodium oxybate SUNOSI (solriamfetol) WAKIX (pitolisant) * XYREM (sodium oxybate) XYWAV (sodium oxybate) *	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. * Three (3) products, two (2) of which must be a preferred product and one (1) of which must be Sunosi, required before product will be approved.
STIMULANTS AND RELATED AGENTS – LONG-ACTING, AMPHETAMINE-LIKE AGENTS (Clinical criteria applies for members over age 21.) Review Schedule: 4th Quarter		
dextroamphetamine ER dextroamphetamine-amphetamine ER DYANAVEL XR (amphetamine/dextroamphetamine SR) suspension VYVANSE (lisdexamfetamine) capsule	ADDERALL XR (amphetamine/ dextroamphetamine SR 24 HR, IR/ER, 50:50%) ADZENYS XR ODT (amphetamine SR 24 HR, IR/ER, 50:50%) amphetamine ER ODT (generic ADZENYS XR ODT) ARYNTA (lisdexamfetamine) DYANAVEL XR (amphetamine/dextroamphetamine SR) tablet lisdexamfetamine MYDAYIS (mixed amphetamine salts) VYVANSE (lisdexamfetamine) chewable tablet XELSTRYM (dextroamphetamine) patch	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
STIMULANTS AND RELATED AGENTS – LONG-ACTING, METHYLPHENIDATE-LIKE AGENTS (Clinical criteria applies for members over age 21.) Review Schedule: 4th Quarter		
dexamethylphenidate ER methylphenidate CD (generic METADATE CD) methylphenidate ER (generic RITALIN SR) methylphenidate ER 24 (generic CONCERTA) methylphenidate LA (generic RITALIN LA) QUILLICHEW ER (methylphenidate IR/ER, 30:70%) QUILLIVANT XR (methylphenidate IR/ER, 20:80%)	APTENSIO XR (methylphenidate) AZSTARYS (serdexmethylphenidate/ dexmethylphenidate) CONCERTA (methylphenidate SA OSM IR/ER, 22:78%) COTEMPLA XR (methylphenidate IR/ER 25:75%) DAYTRANA (methylphenidate) patch FOCALIN XR (dexmethylphenidate SR 24 HR) JORNAY PM (methylphenidate ER) methylphenidate XR (generic Aptensio XR) methylphenidate (transdermal) patch TD24 RELEXII ER 24 (methylphenidate ER OSM IR/ER, 22:78%)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
STIMULANTS AND RELATED AGENTS – LONG-ACTING, OTHER (Clinical criteria applies for members over age 21.) Review Schedule: 4th Quarter		
atomoxetine clonidine ER 0.1 mg tablet guanfacine ER	INTUNIV (guanfacine ER) ONYDA XR (clonidine hydrochloride) QELBREE (viloxazine hydrochloride) STRATTERA (atomoxetine)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
STIMULANTS AND RELATED AGENTS – SHORT-ACTING, AMPHETAMINE-LIKE AGENTS (Clinical criteria applies for members over age 21.) Review Schedule: 4th Quarter		
dextroamphetamine/amphetamine IR dextroamphetamine IR tablet PROCENTRA (dextroamphetamine)	ADDERALL (amphetamine/dextroamphetamine) amphetamine tablet dextroamphetamine solution EVEKEO (amphetamine) ODT, tablet methamphetamine ZENZEDI (dextroamphetamine)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. Dose optimization required
STIMULANTS AND RELATED AGENTS – SHORT-ACTING, METHYLPHENIDATE-LIKE AGENTS (Clinical criteria applies for members over age 21.) Review Schedule: 4th Quarter		
dexmethylphenidate IR methylphenidate IR methylphenidate solution	FOCALIN (dexmethylphenidate) METHYLIN (methylphenidate) solution methylphenidate chewable tablet RITALIN (methylphenidate)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
SMOKING CESSATION		
SMOKING CESSATION PRODUCTS		Review Schedule: 1st Quarter
bupropion SR nicotine lozenge, gum, patch varenicline	CHANTIX (varenicline) NICOTROL NS	<ul style="list-style-type: none"> • Please refer to the Delaware OTC Rebate List on the DMAP Provider Pharmacy Portal. • Two (2) preferred products required before a non-preferred product will be approved.
TOPICAL PRODUCTS		
ANTIBIOTICS, TOPICAL		Review Schedule: 1st Quarter
bacitracin bacitracin zinc bacitracin/polymyxin gentamicin mupirocin ointment neomycin/bacitracin/polymyxin	bacitracin/pramoxine CENTANY (mupirocin) mupirocin cream neomycin/bacitracin/polymyxin/pramoxine neomycin/polymyxin/pramoxine NEO-SYNALAR (fluocinolone/neomycin) XEPI (ozenoxacin)	<ul style="list-style-type: none"> • Two (2) preferred products required before a non-preferred product will be approved.
ANTIFUNGALS, TOPICAL		Review Schedule: 4th Quarter
butenafine ciclopirox cream, solution clotrimazole cream clotrimazole/betamethasone cream, lotion econazole cream ketoconazole cream, shampoo miconazole nitrate solution w/ applicator nystatin nystatin/triamcinolone ointment	ALEVAZOL (clotrimazole) CICLODAN (ciclopirox) ciclopirox gel, shampoo, suspension clotrimazole solution econazole foam ERTACZO (sertaconazole) EXELDERM (sulconazole) ketoconazole foam KETODAN (ketoconazole) LOPROX (ciclopirox) miconazole miconazole/zinc/petrolatum NAFTIN (naftifine) naftifine nystatin/triamcinolone cream oxiconazole OXISTAT (oxiconazole) terbinafine tolnaftate VOTRIZA-AL (clotrimazole) lotion VUSION (miconazole/zinc/petrolatum)	<ul style="list-style-type: none"> • Two (2) preferred products required before a non-preferred product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
ANTIPARASITICS, TOPICAL Review Schedule: 4th Quarter		
NATROBA (spinosad) permethrin piperonyl butoxide/pyrethrins	CROTAN (crotamiton) ivermectin lotion malathion OVIDE (malathion) lotion SKLICE (ivermectin) spinosad VANALICE (pyrethrins/piperonyl butoxide)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
ANTIPSORIATIC AGENTS, ORAL Review Schedule: 3rd Quarter		
acitretin	methoxsalen	<ul style="list-style-type: none"> One (1) preferred product required before a non-preferred product will be approved.
ANTIPSORIATIC AGENTS, TOPICAL Review Schedule: 4th Quarter		
calcipotriene cream, ointment, solution ZORYVE 0.3% (roflumilast) *	calcipotriene foam calcipotriene/betamethasone calcitriol ENSTILAR (calcipotriene/betamethasone) SORILUX (calcipotriene) tazarotene cream, gel TAZORAC (tazarotene) VECTICAL (calcitriol) VTAMA (tapinarof) **	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. * Step through a preferred topical corticosteroid or preferred topical calcipotriene product required. ** Two (2) products, one (1) of which must be a preferred calcipotriene product and one (1) of which must be Zoryve 0.3%, required before product will be approved.
ANTIVIRALS, TOPICAL Review Schedule: 4th Quarter		
acyclovir ointment docosanol	acyclovir cream DENAVIR (penciclovir) penciclovir cream	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
IMMUNOMODULATORS, ATOPIC DERMATITIS (Clinical criteria applies to class. All agents require a prior authorization.) Review Schedule: 4th Quarter		
EUCRISA (crisaborole) * pimecrolimus tacrolimus ZORYVE 0.05%, 0.15% (roflumilast) *	ADBRY (tralokinumab-ldrm) ANZUPGO (delgocitinib) CIBINQO (abrocitinib) EBGLYSS (lebrikizumab-lbkz) NEMLUVIO (nemolizumab-ilto) OPZELURA (ruxolitinib)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved. Quantity limits are in place: 400 grams per year * Step through a topical corticosteroid or topical calcineurin product required

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
IMMUNOMODULATORS, TOPICAL		Review Schedule: 3rd Quarter
imiquimod 3.75% cream imiquimod 5% cream packet	imiquimod cream pump VEREGEN (sinecatechins)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
OPHTHALMICS, ALLERGIC CONJUNCTIVITIS		Review Schedule: 3rd Quarter
ALAWAY (ketotifen) azelastine cromolyn ketotifen olopatadine 0.1%, 0.2% OTC olopatadine 0.2% RX	ALREX (loteprednol) bepotastine BEPREVE (bepotastine) epinastine LASTACRAFT OTC (alcaftadine) olopatadine 0.1% RX olopatadine 0.7% PATADAY (olopatadine) ZADITOR (ketotifen) ZERVIAE (cetirizine)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
OPHTHALMICS, ANTIBIOTICS		Review Schedule: 3rd Quarter
bacitracin/polymyxin CILOXAN (ciprofloxacin) ointment ciprofloxacin erythromycin gentamicin moxifloxacin (generic VIGAMOX) ofloxacin POLYCIN (bacitracin/polymyxin) polymyxin/trimethoprim tobramycin	AZASITE (azithromycin) bacitracin bacitracin/polymyxin besifloxacin BESIVANCE (besifloxacin) gatifloxacin levofloxacin moxifloxacin viscous (generic MOXEZA) NATACYN (natamycin) neomycin/bacitracin/polymyxin neomycin/polymyxin/gramicidin OCUFLOX (ofloxacin) POLYTRIM (polymyxin/trimethoprim) sulfacetamide TOBREX (tobramycin) VIGAMOX (moxifloxacin) XDEMVY (lotilaner) ZYMAXID (gatifloxacin)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
OPHTHALMICS, ANTIBIOTIC-STEROID COMBINATION		Review Schedule: 3rd Quarter
neomycin/polymyxin/dexamethasone sulfacetamide/prednisolone TOBRADEX (tobramycin/dexamethasone) ointment	neomycin/bacitracin/polymyxin/HC neomycin/polymyxin/HC NEO-POLYCIN HC (neomycin/bacitracin/ polymyxin/HC) TOBRADEX ST (tobramycin/dexamethasone) tobramycin/dexamethasone tobramycin/loteprednol ZYLET (tobramycin/loteprednol)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
Review Schedule: 3rd Quarter		
<p>dexamethasone diclofenac FLAREX (fluorometholone) fluorometholone flurbiprofen FML FORTE (fluorometholone) ketorolac (all strengths) LOTEMAX (loteprednol) ointment MAXIDEX (dexamethasone) NEVANAC (nepafenac) PRED MILD (prednisolone) prednisolone</p>	<p>ACULAR (ketorolac) ACULAR LS (ketorolac) ACUVAIL (ketorolac) bromfenac BROMSITE (bromfenac) clobetasol DEXTENZA (dexamethasone) difluprednate DUREZOL (difluprednate) EYSUVIS (loteprednol) FML LIQUFILM (fluorometholone) ILEVRO (nepafenac) ILUVIEN (fluocinolone acetate) INVELTYS (loteprednol) LOTEMAX (loteprednol) gel LOTEMAX SM (loteprednol) loteprednol OZURDEX (dexamethasone) PROLENSA (bromfenac) RETISERT (fluocinolone acetonide) TRIESENCE (triamcinolone acetonide) XIPERE (triamcinolone acetonide) YUTIQ (fluocinolone acetonide)</p>	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
Review Schedule: 3rd Quarter		
<p>ALPHAGAN P (brimonidine) brimonidine 0.2% carteolol COMBIGAN (brimonidine/timolol) dorzolamide dorzolamide/timolol drops ISTALOL (timolol maleate) latanoprost levobunolol pilocarpine SIMBRINZA (brinzolamide/brimonidine) timolol maleate solution travoprost</p>	<p>apraclonidine AZOPT (brinzolamide) betaxolol BETIMOL (timolol hemihydrate) BETOPTIC (betaxolol) BETOPTIC S (betaxolol) brimatoprost brimonidine/timolol brimonidine 0.1%, 0.15% brinzolamide COSOPT (dorzolamide/timolol) COSOPT PF (dorzolamide/timolol) dorzolamide/timolol (PF) droperette iDOSE (travoprost) iopidine IYUZEH (latanoprost/PF) LUMIGAN (bimatoprost) phospholine iodine RHOPRESSA (netarsudil) ROCKLATAN (netarsudil/latanoprost)</p>	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
	tafluprost (PF) droperette timolol hemihydrate timolol maleate gel timolol maleate drop daily timolol maleate (PF) droperette TIMOPTIC (timolol) TIMOPTIC XE (timolol) TRAVATAN Z (travoprost) VYZULTA (latanoprostene bunod) XALATAN (latanoprost) XELPROS (latanoprost) ZIOPTAN (tafluprost)	
OPHTHALMICS, IMMUNOMODULATORS		Review Schedule: 4th Quarter
RESTASIS (cyclosporine) vial XIIDRA (lifitegrast)	CEQUA (cyclosporine) cyclosporine droperettes MIEBO (perfluorohexyloctane) RESTASIS MULTIDOSE (cyclosporine) TRYPTYR (acoltremon) TYRVAYA (varenicline) VERKAZIA (cyclosporine) VEVYE (cyclosporine)	<ul style="list-style-type: none"> Two (2) preferred product required before a non-preferred product will be approved.
OTIC ANTIBIOTICS		Review Schedule: 3rd Quarter
CIPRO HC (ciprofloxacin/hydrocortisone) CORTISPORIN-TC (neomycin/colistin/hydrocortisone/thonzonium) neomycin/polymyxin/hydrocortisone ofloxacin	ciprofloxacin ciprofloxacin/dexamethasone ciprofloxacin/fluocinolone ciprofloxacin/hydrocortisone OTOVEL (ciprofloxacin/fluocinolone acetate)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.
OTIC ANTI-INFECTIVES, ANESTHETICS		Review Schedule: 1st Quarter
acetic acid	acetic acid/hydrocortisone	<ul style="list-style-type: none"> One (1) preferred product required before a non-preferred product will be approved.
ROSACEA AGENTS, TOPICAL		Review Schedule: 1st Quarter
azelaic acid (generic FINACEA) metronidazole 0.75% cream, 0.75% gel metronidazole 1% gel pump	brimonidine EPSOLAY (benzoyl peroxide) FINACEA (azelaic acid) ivermectin cream METROCREAM (metronidazole) METROGEL (metronidazole) metronidazole 0.75% lotion metronidazole 0.1% gel MIRVASO (brimonidine) RHOFADÉ (oxymetazoline)	<ul style="list-style-type: none"> Two (2) preferred products required before a non-preferred product will be approved.

PREFERRED AGENTS	NON-PREFERRED AGENTS Prior authorization is required	CRITERION
	ROSADAN (metronidazole) SOOLANTRA (ivermectin)	
STEROIDS, TOPICAL		Review Schedule: 3rd Quarter
clobetasol ointment, solution fluocinolone topical solution, oil fluocinonide ointment 0.05% fluticasone cream, ointment hydrocortisone (except 2.5% solution) hydrocortisone acetate mometasone SCALPICIN (hydrocortisone) triamcinolone cream, lotion, 0.025%, 0.1%, 0.5% ointment		alclometasone amcinonide APEXICON E (diflorasone diacetate) betamethasone dipropionate betamethasone dipropionate/propylene glycol betamethasone valerate clobetasol cream, foam, gel, lotion, shampoo, spray clocortolone CLOBEX (clobetasol) CLODAN (clobetasol) CORDRAN (fludroxycortide) DERMACINRX DERMA-SMOOTH FS (fluocinolone) DERMASORB (triamcinolone) desonide desoximetasone diflorasone fluocinolone cream, ointment fluocinonide (except 0.05% ointment) flurandrenolide fluticasone lotion halcinonide halobetasol hydrocortisone 2.5% solution hydrocortisone butyrate hydrocortisone valerate LEXETTE (halobetasol propionate) MICORT-HC (hydrocortisone acetate) OLUX-E (clobetasol) PANDEL (hydrocortisone probutate) prednicarbate SERNIVO (betamethasone dipropionate) SYNALAR (fluocinolone) TEXACORT (hydrocortisone) TOPICORT (desoximetasone) TOVET (clobetasol) triamcinolone 0.05% ointment, aerosol ULTRAVATE (halobetasol)